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“Courage is going from failure to failure without losing enthusiasm.”  
– Winston Churchill 
“If one way be better than another, that you may be sure is nature’s way.” 
– Aristotle 
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1. Introduction 
1.1. Cytomegalovirus (CMV)  
The cytomegalovirus (CMV) belongs to the Betaherpesvirinae subfamily of the 
family Herpesviridae (Figure 1.1) (1). Several species of CMV have been identified 
and classified for different mammals. The genus Cytomegalovirus includes human 
cytomegalovirus (HCMV) (also known as human herpesvirus 5) and other primate 
CMV species, including chimpanzee cytomegalovirus (CCMV) that infects 
chimpanzees and orangutans, and rhesus cytomegalovirus (RhCMV) and simian 
cytomegalovirus (SCMV) that infect macaques. The genus Muromegalovirus includes 
two rodent CMV species: murine cytomegalovirus (MCMV) and rat cytomegalovirus 
(RCMV). In addition, there are several CMV species identified in distinct mammals 
(e.g. guinea pig, pig) that are not completely classified. 
 
Figure 1.1  Taxonomic organisation of the Betaherpesvirinae subfamily of the family 
Herpesviridae.  
All CMV species share a number of characteristics in their infection pattern in vitro 
and in vivo (2). They replicate slowly in cell culture, and infected cells frequently 
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become enlarged (cytomegalia). All CMV species have a strict species-specificity. In 
immunocompetent hosts, CMV infection is generally asymptomatic, and then 
persistence or latency is established. In immunocompromised hosts, CMV infection 
can result in severe manifestations that are recognizable by the owl's eye-like 
cytopathology in tissues.  
HCMV is the most studied of all CMVs, but little is known about natural primary 
infections. Due to the strict species-specificity of CMV, HCMV cannot be studied 
experimentally in animal models. Therefore, animal CMV infections in their own 
hosts are generally used to mimic HCMV infection in humans. MCMV infection in 
mice has been mostly used as a model to study HCMV infections in humans (2). 
MCMV and HCMV exhibit a range of common biological features in pathogenesis, 
immunomodulation and latency, and mice can be genetically manipulated, are 
cost-effective and relatively easy to handle. However, the differences of anatomy 
between humans and mice should be considered during the study of animal model. 
 
1.2. History of MCMV 
In the 1930s, acidophilic intranuclear inclusion bodies were found in the 
submandibular glands of mice (Figure 1.2A), and the etiological agent could be 
transmitted by the inoculation of submandibular gland homogenates into healthy mice, 
which caused a variety of histopathological changes in many tissues (3, 4). The 
etiological agent was believed to be a virus, simply named mouse salivary gland virus 
(MSGV).  
In 1954, MSGV was first isolated in murine cell cultures from salivary glands of mice 
by Margaret Gladys Smith (5). The prototype strain was named ‘Smith strain’ (Figure 
1.2B). To reflect the histology of MSGV-associated lesions (cytomegalic structures) 
and to exemplify that MSGV is found in sites other than salivary glands, the original 
term “mouse salivary gland virus” was replaced by the term “murine cytomegalovirus” 
in 1966 (6).  
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   A.             B.   
Figure 1.2 (A) A hypertrophied acinar cell in the submandibular gland of a 4-weeks old 
mouse. The nucleus is enlarged and contains a large inclusion body surrounded by a clear 
space (1). (B) Mouse salivary gland virus (M.S.G.V.) Smith, ATCC VR-194 batch of 9/75, 
distributed by the American Type Culture Collection (7). 
 
Over the last 30 years, MCMV has become one of the best-studied viruses of 
laboratory mice and is the subject of a very extensive literature. There are several 
reasons for this.  
First, because of the strict species-specificity of the CMV, HCMV cannot be studied 
experimentally in animal models. Since MCMV infection of mice shares many 
features with HCMV infection of humans, the murine MCMV model has been 
extensively used to study HCMV infection in humans.  
Second, there has been strong interest in how MCMV copes with the immune system. 
Immune responses in mice infected with MCMV involve both the innate and adaptive 
arms of the immune system. MCMV has evolved numerous strategies to evade 
immune control and causes persistent and/or latent infection.  
Finally, the strong growth of molecular virology has significantly influenced the 
direction of research on MCMV. The genomes of MCMV and several other CMVs 
have been sequenced, and this information has been enormously valuable for 
understanding gene functions and virus-host interactions. 
 
1.3. Characteristics of MCMV 
1.3.1. Virion structure and replication  
1.3.1.1. Virion structure   
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Herpesvirus virions are spherical and consist of four morphologically distinct 
elements: core, capsid, tegument and envelope (Figure 1.3). The core encompasses 
the double-stranded deoxyribonucleic acid (dsDNA) viral genome, which is packaged 
as a single linear molecule into the protein capsid that exhibits an icosahedral 
symmetry. The tegument is a poorly defined layer of proteinaceous material between 
the capsid and envelope. The envelope is a lipid bilayer that contains a number of 
different viral glycoproteins (8).  
 
Figure 1.3  Structure of a herpesvirus virion. The virion contains a dsDNA packaged within 
capsid. The capsid is surrounded by a tegument and the outer sphere is an envelope that 
contains numerous different viral glycoproteins. 
While the diameter of a single virion of MCMV is approximately 230 nanometer (nm), 
the virions are quite pleiomorphic and may include a high proportion of multicapsid 
virions containing a number of capsids enclosed within a common membrane (9). The 
production of multicapsid virions appears to be a unique property of MCMV.  
The genome size of MCMV is approximately 230 kilo base pairs (kbp) (10), which is 
very similar in size to the genomes of HCMV and RCMV (11, 12). The genome of 
MCMV contains about 200 open reading frames (ORFs) (10, 13). The genomes of 
MCMV and HCMV are co-linear over the central 180 kbp, and there are significant 
similarities to the HCMV genome, especially for 78 ORFs located in the central 
regions of the genome (10). The genome of MCMV is highly conserved in the centre 
of the genome but is variable at the genomic termini, where the known and putative 
immune evasion genes reside (14). 
 
1.3.1.2. Replication of MCMV   
The life cycle of MCMV is initiated when virions bind to receptors on susceptible 
Capsid 
?
Glycoprotein 
 ?
Tegument 
 ?
DNA 
?
Envelope ?
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cells and enter the cytoplasm, where the capsid is transported to the nucleus. 
The cellular receptors used by MCMV have not been demonstrated conclusively. 
More than one molecule is likely to be involved. The major histocompatibility 
complex class I (MHC-I) molecule (15) and beta-2-microglobulin (β2m) (16) have 
been demonstrated to facilitate the entry of MCMV in vitro, although a significant 
role for MHC class I molecules was not confirmed by others in vitro and in vivo (17, 
18). In addition, heparan sulfate proteoglycans (HSPGs) contribute to MCMV binding 
and entry (19). These molecules also contribute to the binding of HCMV to target 
cells (20). 
HCMV interacts with the epidermal growth factor receptor (EGFR) (21) and integrin 
αvβ3 (22) as co-receptors for viral entry, using HCMV glycoprotein B (gB) and 
glycoprotein H (gH) as ligands, respectively. Integrin αvβl is also a co-receptor for 
HCMV (23). The binding of HCMV to these molecules initiates translocation of 
integrin αvβ3 into lipid rafts in the cell membrane. This results in interaction with 
EGFR and a coordinated signaling, which triggers potent cooperative effects in target 
cells that appear to be necessary for successful viral infection (21). The role of these 
molecules as possible co-receptors in MCMV infection is not determined. 
MCMV DNA replication appears to follow the same sequence of events that occurs 
during replication of other herpesviruses, via circular and/or concatemeric 
intermediates (24). The sequences at the termini of the genome fuse via a 3' 
nucleotide extension to form the intermediates for MCMV replication, which occurs 
by a rolling-circle model (24). MCMV genomes circularize as soon as 2 hours post 
infection (hpi) (24). Host DNA synthesis is inhibited by more than 95% by 10-12 hpi 
(25), and the onset of viral DNA synthesis in mouse embryo fibroblasts (MEF) occurs 
during 8-16 hpi depending on the mitotic phase of the host cells (25-28). By 22 hpi 
the equivalent of 900 viral genomes per cell have been synthesized (29). 
Gene expression is temporally controlled in a cascade manner. All betaherpesviruses 
including MCMV (30) have three gene families, α, β and γ, that are temporally 
regulated. These genes are expressed in the immediate early (IE), early (E), and late 
(L) phases of viral replication, respectively. The IE phase occurs immediately after 
viral DNA enters the nucleus and is controlled by the major IE promoter (MIEP) in 
MCMV (31). The IE genes do not require de novo protein synthesis, and their 
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transcription is not inhibited by protein inhibitors, such as cyclohexamide (32).  
While IE gene expression is confined to discrete regions of the genome, early gene 
transcripts come from various regions of the genome (30). Entry into the E phase 
depends on de novo protein synthesis and is therefore inhibited by cyclohexamide. 
There is an absolute requirement for IE gene expression prior to E gene expression 
(33), and E gene expression can be regulated by proteins derived from IE genes or 
from other E genes (34). Genes transcribed during the E phase of viral replication 
include those required for entry into the L phase of viral replication, as well as other 
genes, such as the immune evasion genes (35).  
Entry into the L phase of viral replication requires DNA synthesis and is consequently 
inhibited by phosphonoacetic acid (32). MCMV DNA replication requires proteins 
synthesized during the E phase of replication and occurs in the nucleus. The L phase 
of viral replication starts approximately 16 hpi (25). However, both viral DNA 
replication and the kinetics of virus production are likely to depend on the cell culture 
system or cell type studied (29, 36). L phase genes mostly encode structural proteins. 
The assembly and egress of CMV, including that of MCMV, also share features of 
other herpesviruses (37). However, the formation of multicapsid virions appears to be 
unique to MCMV. Multicapsid virions are particles with 2 or more capsids enclosed 
in a common envelope (9). It has been postulated (38) that they are formed when 
capsids exit the nucleus via nuclear pores and enter cytoplasmic aggregates of capsids. 
These capsids then receive an envelope via budding into extended cytoplasmic 
vacuoles derived from the Golgi apparatus. The multicapsid virions are also believed 
to be released from the cell by exocytosis (38).  
 
1.3.2. Propagation of MCMV in vitro 
1.3.2.1. Permissive murine cells 
MCMV can be propagated in a variety of cells or cell lines in vitro (39), and generally 
replicates most productively in murine embryo fibroblasts (MEF) and murine 
fibroblastic cell lines (40). Cell lines that support productive MCMV infection also 
include NIH 3T3 cells and murine bone marrow stromal cell line M2-10B4 (41). 
However, for the detection of MCMV by plaque assay, MEF are more sensitive than 
the latter cell lines (42).    
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1.3.2.2. Features of MCMV replication in vitro 
Following entry of the virus into the permissive cells, there is an eclipse period of 
16-18 hours before infectious progeny can be detected. The eclipse period is followed 
by the release of extracellular virus, which continues over 18-36 hours post 
inoculation (hpi) (39).  
A feature of MCMV infection is the induction of a characteristic cytopathic effect 
(CPE) in which nuclear and cytoplasmic swelling and chromatin margination occurs 
(43) and the formation of both intranuclear and intracytoplasmic inclusions is 
observed (44). These intracellular changes are known as cytomegalia.  
Another feature of MCMV infection in vitro is centrifugal enhancement of infectivity, 
which was first reported by Osborn and Walker (45). Low-speed centrifugation of the 
viral inoculum against the cell monolayer at 1000 × g for 30 minutes results in a 10 to 
100-fold increase in the number of PFU that are detected. The phenomenon is also 
applicable to HCMV, but not to herpes simplex virus or pseudorabies virus.       
1.4. Pathogenesis of MCMV 
1.4.1. Factors influencing the outcome of MCMV infection 
1.4.1.1. Virus strain 
A number of MCMV strains have been described (Table 1.1), but only the Smith and 
K181 strains have been widely used. The Smith strain was derived from the original 
MCMV isolate by Margaret Gladys Smith (5) and is the most commonly used strain.  
Table 1.1  Fully sequenced MCMV strains. 
Strain Location of isolation Genome size (bp) Accession number Year Ref. 
Smith 
K181 
N1 
G4 
C4A 
C4B 
C4C 
C4D 
WP15B 
WT1 
AA18D 
N07 
St. Louis, USA 
Wisconsin, USA 
Nannup, Australia 
Geraldton, Australia 
Canberra, Australia 
Canberra, Australia 
Canberra, Australia 
Canberra, Australia 
Walpeup, Australia 
USA 
Macquarie Island, Australia 
Beacon Island, Australia 
230,278 
230,301 
229,884 
230,227 
230,111 
230,154 
229,924 
229,935 
230,118 
230,408 
229,543 
229,452 
NC_004065 
AM886412 
HE610454 
EU579859 
EU579861 
HE610452 
HE610453 
HE610456 
EU579860 
GU305914 
HE610451 
HE610455 
1954 
1976 
1993 
1993 
2006 
2006 
2006 
2006 
2008 
2010 
2013 
2013 
(5) 
(9) 
(46) 
(46) 
(47) 
(47) 
(47) 
(47) 
(48) 
(49) 
(50) 
(50) 
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The Smith strain has been passaged in many different laboratories, resulting in the 
emergence of variants that exhibit different biological properties (40). For example, 
variant Vancouver strain emerged following the serial passage of the Smith strain in 
cell culture in Hudson's laboratory over a number of years (51). This strain exhibits an 
altered tissue tropism, failing to grow in the salivary glands, while exhibiting 
enhanced in vitro growth compared to the parental Smith strain.  
The K181 strain arose in Osborn's laboratory from the salivary gland passage of the 
Smith strain in mice, selecting for more virulent variants (52). The K181 strain 
reaches 100-fold higher titers in the salivary glands than the Smith strain (52), but 
exhibits different plaque morphology and lower yield in cell culture (53).  
Recently, a Belgian strain, HaNa1, was isolated from a single mouse (Mus musculus 
domesticus) by Hans Nauwynck. In vitro, the HaNa1 strain grows to a ~10-fold lower 
yield than the Smith strain in MEF. In vivo, the HaNa1 strain reaches higher titers in 
the nasal mucosa and submandibular glands than the Smith strain but does not 
produce infectious virus in the visceral organs of adult BALB/c mice (54). 
This issue has also been recognized in HCMV research (55). The widely used AD169 
has been maintained by in vitro culture, mainly in fibroblastic cell lines, and multiple 
variants have arisen in different laboratories. In addition to the use of other strains of 
HCMV such as Toledo, which was more recently derived from a clinical specimen, 
and Towne, a strong emphasis in recent HCMV research has been placed on the use 
of freshly derived clinical isolates. Currently, the bacterial artificial chromosome 
(BAC) technology has been used widely to repair all of these mutations to generate a 
BAC that corresponds to a kind of prototypic HCMV WT genome (56). As expected, 
the virus derived from this BAC has many properties in common with clinical HCMV 
isolates, including slow growth and cell association (57). 
 
1.4.1.2. Mouse strain 
The natural host of MCMV is the house mouse (Mus musculus (M.m)), which 
comprises M. m. musculus, M. m. domesticus, M. m. castaneus, M. m. molossinus and 
M. m. gentilulus. Figure 1.4 shows the distribution pattern of the Mus musculus with 
asterisks indicating locations of mice used to isolate MCMV strains. To date all the 
MCMV strains were isolated from M. m. domesticus.  
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Figure 1.4  Distribution pattern of the Mus musculus with asterisks indicating locations of 
mice used to isolate MCMV strains. To date all the MCMV strains isolated from free-living 
mice were circulating in M. m. domesticus populations. Adapted from (14). 
In animal facilities, inbred mice have been widely used for studying MCMV. Inbred 
mouse strains vary markedly in their susceptibility to MCMV infection. Early genetic 
studies on the susceptibility of mice to MCMV infection revealed the dominant 
impact of two loci: the histocompatibility-2 (H-2) locus on mouse chromosome 17 
and a non-H-2 locus on mouse chromosome 6 (58), within a region named the 
‘Natural Killer gene Complex’ (NKC). The H-2 locus encodes the mouse major 
histocompatibility class I that are the self ligands recognized by many NK receptors 
(Figure 1.5). Each mouse strain has a unique MHC haplotype (e.g. H-2d (BALB/c), 
H-2b (C57BL/6), H-2g7 (NOD)). The NKC encodes several multigene families of NK 
receptors of which the Ly49 family is associated with the susceptibility to MCMV 
infection (59-63). Under normal conditions, inhibitory Ly49 receptors recognize 
self-MHC-I molecules and NK cell activation is prevented. During an MCMV 
infection, MHC-I molecules are down-regulated, leaving inhibitory Ly49 receptors 
unengaged, which causes NK activation.  
!
!
!
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Figure 1.5  Major NK cell receptors and their ligands.  
The number of Ly49 haplotype genes varies among different mouse strains (Figure 
1.6). The affinity of each inhibitory receptor for a given MHC-I haplotype is different. 
Therefore, the ability of binding of MHC-I and Ly49 receptors and to mount an 
effective NK cell response varies among different mouse strains, which may have an 
impact on their susceptibility to an MCMV infection. In addition, evolutionary 
pressure on the host may result in the emergence of activating Ly49 receptors capable 
of MCMV recognition. It is well known that the activating Ly49H receptors mediate 
the activation of NK cells by binding to an MCMV-encoded ligand, m157 protein 
(64-66). Therefore, Ly49H- mice may show increased virus titers in tissues than 
Ly49H+ mice during an MCMV infection (66). 
!"#$%%%&'
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Figure 1.6  Mouse NK cell complex and different Ly49 haplotypes. Schematic organization 
of the NKC (upper panel) and the Ly49 gene cluster in BALB/c, C57BL/6, and NOD strains 
(lower panel). Activating receptors are shown in green, inhibitory in red, and pseudogenes are 
shown in white and are asterisked. Ly49E has the potential to transduce both activating and 
inhibitory signals (63). 
 
1.4.1.3. Age 
MCMV is more virulent in young, immunologically immature mice than in adults. In 
newborn BALB/c mice, the lethal dose 50 (LD50) dose for the K181 strain inoculated 
intraperitoneally is approximately 2 plaque forming unit (PFU). However, in adult 
BALB/c, the LD50 is approximately 5×104 PFU (67). The resistance of mice to lethal 
MCMV infection matures after weaning (68, 69) and continues to increase until 
around 8 weeks of age, after which it changes only a little bit (58). For this reason, it 
is important that the age of mice used in experimental work is accurately described.  
The increased susceptibility to MCMV infection is believed to be partly due to an 
immature immune system. The immune systems of neonates and adults differ 
substantially. In neonates, total lymphocyte and dendritic cell numbers are 
significantly lower compared with adults (70). Lymphoid follicles, follicular dendritic 
cell networks and germinal center structures of secondary lymphoid tissue, known to 
be crucial for antibody development, are absent at birth and form between a few days 
to a few weeks of age (71). The complete development of antigen-presenting cells is 
achieved several weeks after birth (72). Although control of CMV replication is 
limited during early life compared to adult life, the anti-viral innate and adaptive 
immune responses can be detected (73).   
 
/c?
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1.4.1.4. Inoculation routes 
The route used by MCMV to enter the host has not yet been clearly determined. The 
pathogenesis of MCMV infection in adult mice has been studied using a variety of 
inoculation routes (Figure 1.7) (40). Most studies have employed the intraperitoneal 
route, which results in the direct infection of visceral organs such as spleen and liver 
(66). Besides, intranasal (with anesthesia) (74, 75), intravenous (76, 77), intracerebral 
(78, 79), intraocular (80, 81) and footpad (82, 83) inoculations have also been used. 
So far, studies of the kinetics of infection, organ and tissue tropism, and the host 
response following naturally acquired infection have not been performed. Generally, 
inoculations by intranasal (without anesthesia) and peroral routes are considered to be 
the best to induce a natural infection. 
 
Figure 1.7  Inoculation routes for studying MCMV infections in adult mice. The mouse 
model picture is derived from artist Laurie O'Keefe with her permission.  
 
1.4.2. Primary infection  
1.4.2.1. General features 
It has been over 80 years since the distribution of MCMV in tissues of infected mice 
was reported (4). Many studies followed, but they did not give a clear picture of the 
viral pathogenesis. Most of these studies have utilized the intraperitoneal route with 
highly passaged strains, and MCMV showed a tropism for many tissues and a variety 
of functionally different cells within these tissues. 
In immunocompetent adult mice, infection of MCMV is usually asymptomatic, and it 
is not associated with serious organ damage. In contrast, infection of 
immunocompromised adult mice with MCMV is associated with a high level of virus 
replication and multi-organ damage, such as interstitial pneumonia, hepatitis and 
spleen necrosis. In neonatal mice, intraperitoneal infection with MCMV results in 
intracerebral?
intraocular?
intranasal?
footpad ?
intraperitoneal ?
intravenous ?
peroral?
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significant morbidity and mortality (84). 
 
1.4.2.2. Salivary glands 
The salivary glands of mice consist of three paired major glands: submandibular, 
sublingual and parotid glands. All three major salivary glands support MCMV 
replication, but MCMV infection appears to be more pronounced in the 
submandibular glands, followed by the sublingual and parotid glands (85).  
No matter what inoculation route is used, evidence for replication in the salivary 
glands is not obtained until at least 7 dpi. The infection is characterized by an acute 
phase, giving high yields of virus, followed by a persistent infection in susceptible 
mice. The acinar epithelial cells are the major sites of MCMV replication in the 
salivary glands (54, 86), from which the virus is shed into ducts and drained with the 
saliva to the mouth (85, 87).  
Salivary glands are the main site of MCMV persistent infection. On the one hand, 
MCMV persistence in the salivary glands is controlled by at least three viral genes, 
m33 (88, 89), m131/129 (MCMV-encoded CC chemokine 2, MCK-2) (90) and m133 
(91, 92). On the other hand, salivary glands are regarded as privileged sites of virus 
immune evasion (93). The virus is eventually eliminated from the salivary glands by 
effector CD4+ T and not CD8+ T cells. Meanwhile, this mechanism is severely 
dampened by high levels of the immunosuppressive cytokine interleukin-10 (IL-10) in 
the salivary glands.   
 
1.4.2.3. Lungs 
Very little attention was given to lung involvement in the early studies on MCMV 
pathogenesis using the intraperitoneal inoculation route. Since HCMV-associated 
interstitial pneumonitis is a frequent complication in immunosuppressed patients (94), 
lungs are important target organs. In order to establish a lung infection and to mimic 
HCMV-associated interstitial pneumonitis in humans, intranasal inoculation (with 
anesthesia) was used in these studies.  
Interstitial pneumonitis has been reported in the absence of immunosuppression in 
adult BRVS outbred mice following intranasal inoculation (with anesthesia) with 
MCMV. Lungs were reported as a primary target of infection and virus was detected 
as early as 2 dpi in the lungs (75). But in inbred BALB/c mice, immunosuppression is 
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usually required for interstitial pneumonitis (95, 96). Following intranasal inoculation 
(with anesthesia) with MCMV, cyclophosphamide-treated mice developed severe 
interstitial pneumonia, but in normal mice MCMV did not result in any histological 
abnormalities. Recently, Stahl et al. inoculated neonatal BALB/c mice via the trachea 
and then detected infected cells in the lungs within 1 dpi (74). Comparative analysis 
of neonatal and adult mice revealed a delayed control of virus replication in the 
neonatal lungs, characterized by a delayed expansion of CD8+ T cell clones in 
neonates. 
 
1.4.2.4. Spleen   
The spleen is the most important visceral organ in an acute MCMV infection. 
Following intraperitoneal inoculation, the spleen is the initial infection site (97). 
Numerous studies have reported several features of the spleen response to MCMV 
infection (usually via intraperitoneal route with salivary glands passaged virus), e.g. 
enlargement and necrosis. Usually, only certain mouse strains (e.g. BALB/c) are 
susceptible to necrosis and this correlates with high virus titers (98).   
The first target cell in the spleen remains controversial. Mims and Gould showed that 
the first infected cells were medium to large mononuclear cells in the perifollicular 
areas and red pulp (98), but others noted the involvement of reticular or stromal cells 
as well (97, 99). In acute MCMV infection, NK cells have been reported to be crucial 
to control the virus replication in the spleen. NK cells utilize a perforin-dependent 
effector mechanism to regulate MCMV infection in the spleen (100, 101).  
 
1.4.2.5. Liver 
The liver is a major target of MCMV infection soon after intraperitoneal or 
intravenous inoculation. Hepatocytes are infected as early as 1 days post inoculation 
(dpi), and nuclear and cytoplasmic inclusions are observed (44, 102). Virus titers peak 
in the liver of BALB/c mice at 2-4 dpi (66). Afterwards, virus titers rapidly decrease 
to an undetectable level. Several studies have shown that severe hepatitis, which is 
induced by a lethal dose of MCMV in susceptible mice, is likely to be the cause of 
early mortality (103, 104). 
During the early stage of MCMV infection in the liver, NK cells are important to 
control virus replication in the liver. Interferon-γ (IFN-γ) produced by NK cells is an 
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important effector (100, 105). During late stage of the infection, the production of 
IL-10 in the liver is elevated (106). NK cells are identified as major IL-10 expressing 
cells in the liver after infection, along with T cells and other leukocytes, which 
provide protection from injury by modulating the inflammatory response associated 
with MCMV infection. 
 
1.4.2.6. Central nervous system (CNS) 
Most of the studies on CNS involvement have utilized intracerebral inoculation. 
Neonatal mice were intracerebrally inoculated and cytopathic effects were observed 
within 2 days (107, 108). It finally resulted in a generalized encephalitis, with 
considerable necrosis and a strong inflammatory response. Numerous cell types, 
including neurons in different areas, glial cells and macrophages, showed typical 
nuclear and cytoplasmic inclusions.  
Following intraperitoneal inoculation, virus dissemination within the CNS is a distinct 
feature of MCMV infection in newborn compared with adult mice. In newborn mice, 
virus titers peaked in the CNS at 10-14 dpi and infectious virus was undetectable by 
21 dpi (109). Virus clearance required CD8+ T cells into the CNS (109). The 
differences in the MCMV infection of the brain between neonatal and adult mice can 
be explained not only by the immunological immaturity of neonatal mice, but 
probably also by the fact that in neonatal mice many cell types in the brain are more 
permissive for MCMV infection (110).  
1.4.2.7. Monocytes 
Viremia commonly occurs during MCMV infection, but virus has never been detected 
in a cell-free form in blood. Bloodborne MCMV is associated with cells in the 
peripheral blood mononuclear cell (PBMC) (111-115). During acute infection, viral 
DNA can be detected in the PBMC but infectious virus is not detectable. Productive 
replication can be reactivated from these silently infected PBMC by cocultivation 
with susceptible cells (e.g. MEF). Injection of purified PBMC from infected mice can 
result in infection in healthy mice. Stoddart et al. demonstrated that a mononuclear 
phagocyte serves as a vehicle of the virus, mediating dissemination during acute 
infection (114). Recently, Daley-Bauer et al. have found that cell-associated viremia 
is markedly enhanced by MCK-2, which promotes recruitment of CX3CR1hi 
patrolling monocytes to initial infection sites in the mouse. These CX3CR1hi 
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patrolling monocytes become infected and serve as immune-privileged vehicles to 
transport MCMV via the bloodstream to distal organs (111), where the monocytes 
differentiate into mature macrophages which support a fully productive replication.   
 
1.4.3. Latency and reactivation 
Latency is a status during which the functionally intact, reactivation-competent viral 
genome is maintained without completion of the productive replication cycle, so that 
infectious viral progeny is not formed or released (116).   
Following initial infection, infectious MCMV is quickly cleared from most tissues 
except for the salivary glands (66). The main mediators are the innate immune system, 
especially NK cells (60), as well as adaptive responses, where CD8 T cells are 
critically involved at most sites (117, 118). However, viral genomes remain present in 
latently infected cells. The presence of latent MCMV has been confirmed using 
polymerase chain reaction (PCR) in various sites, including salivary glands (119, 120), 
lungs (121, 122), spleen (123), liver (124) and kidneys (123, 125).  
Although viral DNA is found to be harbored in blood leukocytes for prolonged  
periods (121), the ‘haematopoietic latency’ of MCMV is only transient (126). Some 
subsets of endothelial cells have been identified as the cellular sites of durable latency, 
such as sinusoidal lining cells in spleen (99) and sinusoidal endothelial cells in liver 
(124). 
At the same time, latency can be established as well as maintained at particular organ 
sites, whereas a productive infection continues or recurs elsewhere. This important 
phenomenon may not only be present in different organs of the same animal but also 
in different cell types within the same organ. For instance, in the liver, hepatocytes 
account for most of the virus production (127), whereas latency is established in the 
liver sinusoidal endothelial cells (124), which are very inefficient and transient virus 
producers (127). In other words, latency can be established in the liver sinusoidal 
endothelial cells while, at the same time, acute infection of the liver continues in 
hepatocytes. 
Productive reactivation from latency occurs under appropriate conditions that usually 
involve immunosuppression. The most direct evidence in support of this idea was 
provided by in vivo MCMV reactivation in latently infected mice following selective 
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depletion of innate and adaptive immune cell subsets (128). Selective depletion of NK 
cells (or IFN-γ) largely failed to induce reactivation. Comparing a combined depletion 
of NK cells (or IFN-γ) and CD8 T-cells with a combined depletion of NK cells (or 
IFN-γ) and CD4 T-cells revealed a dominant role for CD8 T-cells in controlling 
latency, further improved by CD4 T-cell help. 
    
1.5. Immune response to MCMV infection 
1.5.1. Innate immune response  
1.5.1.1. Myeloid lineage cells 
Although myeloid cells, such as dendritic cells (DCs) and monocytes/macrophages, 
are normally linked with MCMV dissemination, as well as with promoting adaptive 
immunity via their professional antigen-presenting function, there is some evidence 
for their role in controlling early MCMV infection via direct or indirect regulation of 
the innate defense (Figure 1.8).  
 
Figure 1.8  Cellular and soluble components of the innate immune response to MCMV 
infection (63). Following MCMV infection, DCs and macrophages secrete chemokines and 
cytokines, including IFN-α/β, which are important for the activation of NK cells. NK cells 
exert their antiviral activity through secretion of different cytokines and by direct cytolysis of 
infected cells. Both DCs and NK cells play a role in induction and regulation of the 
subsequent adaptive immune response.   
 
Upon viral infection, plasmacytoid DCs (pDCs) are known as the main producers of 
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IFN-α/β, which inhibit MCMV replication during the early stages of infection (129). 
Conventional DCs (cDCs) produce proinflammatory cytokines (e.g. IL-2, IL-12, 
IL-15, IL-18), which are important for the activation of NK cells (130). Immature 
DCs have a great capacity for endocytosis. Mature DCs are less endocytotic, but 
become more potent in antigen presentation to T-lymphocytes. MCMV can infect 
immature DCs, while impairing antigen uptake, migration and maturation. Infection 
also reduces the expression of MHC-I and co-stimulatory molecules, as well as 
cytokine secretion (36, 131). Mature DCs are either infected at a lower level (36) or 
are not productively infected with MCMV (131).  
Monocytes are also an important component of innate immunity against MCMV. 
Monocytes are recruited to sites of inflammation upon sensing a set of chemokines 
(CCL2, CCL7, and CCL12) after infection. Once inside the tissues, these monocytes 
differentiate into macrophages or DCs. Macrophages are important mediators of 
inflammatory and innate responses to infection and, when activated, infiltrate sites of 
infection (132) to initiate early antiviral responses by producing tumor necrosis factor 
(TNF-α) and IFN-γ (133). The phagocytic function of macrophages is suppressed 
following infection with MCMV (134-136).  
 
1.5.1.2. Interferon (IFN) and other cytokines 
IFN is an important inducer of nonspecific host defenses during acute infection with 
MCMV.  
The production of IFN-α/β is one of the very first responses elicited by the 
recognition of MCMV by the immune system. IFN-α/β is detected very rapidly in 
mice infected intraperitoneally with moderate to high doses (1×104-2×105 PFU) of 
MCMV, with both systemic and spleen/liver levels peaking between 6 hours and 12 
hours (137, 138). IFN-α/β production then wanes, returning to undetectable levels 
between 24 hours and 30 hours (137). A second major wave then occurs at around 36 
hours. The first wave of IFN-α/β is produced by stromal cells (137); the second wave 
of MCMV-induced IFN-α/β production comes from pDCs (139). 
IFN-α/β induces an antiviral state during early times of infection, prior to the 
development of host adaptive immune responses. NK cell activity is enhanced by 
IFN-α/β within the first few days of infection (140). IFN-α/β inhibits MCMV 
replication by impairing viral IE gene transcription (141). IFN-α/β also has regulatory 
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effects on the subsequent expression of endogenous cytokines including IL-12 and 
IFN-γ, which induce protective immune responses during MCMV infection (142).  
IFN-γ is a key regulator during all phases of MCMV infection (143). Control of acute 
infection by MCMV is mediated by IFN-γ secretion by NK cells (105, 132) and T 
cells (144, 145). Functions of IFN-γ during MCMV infection include macrophage 
activation (132), enhancement of antigen presentation by infected cells to CD8+ T 
cells via MHC-I-dependent pathways (146), and inhibition of lytic MCMV replication 
and gene expression at the cellular level (132, 143, 147).  
MCMV induces the production of other cytokines that are detectable in sera during 
the acute stage of infection, including TNF-α, IL-18, IL-12, IL-6, and IL-1α (148, 
149).   
 
1.5.1.3. Natural killer (NK) cells 
Besides innate cytokines, NK cells are equally important in coordinating the complex 
innate defense to MCMV infection. NK cells mediate their function by the secretion 
of cytokines (e.g. IFN-γ, TNF-α), the induction of target cell apoptosis via cell surface 
receptors (105) and the release of cytotoxic granules (granzymes and perforin) (150, 
151). NK cells become activated by two paths during MCMV infection: nonselective 
cytokine-mediated activation and specific activation via receptor-ligand interactions 
(63). For the former, IFN-α/β, IL-12, IL-15 and IL-18 contribute to NK cell activation 
and proliferation after MCMV infection. For example, the production of IFN-α/β is 
required for the accumulation, blastogenesis, and cytotoxicity of NK cells (152-154). 
For the latter, an MCMV-encoded protein, m157, promotes activation and 
proliferation of Ly49H+ NK cells (151, 155).  
NK cells may utilize different mechanisms to regulate viral infection in different 
organs. NK cells accumulate in the spleen and liver at the sites of viral replication in 
an IL-12, IFN-γ and TNF-α dependent manner (156). In the spleen of C57BL/6 mice, 
NK cells control MCMV via a perforin-dependent (IFN-γ independent) cytotoxic 
mechanism (101). In contrast, IFN-γ produced by NK cells is a major immune 
regulator of infection in the liver (101, 105, 154, 157). The formation of early 
inflammatory foci in the liver (158-160) depends on the rapid accumulation of NK 
cells, IFN-γ and macrophage inflammatory protein 1-α (MIP-1α) (152).  
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1.5.2. Adaptive immune response 
1.5.2.1. Humoral immune response 
The humoral immune response is stimulated during acute MCMV infection after 
intraperitoneal inoculation. Serum immunoglobulin M (IgM) antibodies were detected 
in mice as early as 3-5 dpi, while immunoglobulin G (IgG) antibody was detected 
between 5-7 dpi, reaching peak levels at 20 dpi (161). Antibodies to MCMV are 
detectable until 6 months post inoculation in BALB/c mice (162). The IgG isotype 
response to MCMV is predominantly IgG2a (163), which might be associated with 
the production of IFN-γ (145). IgA antibodies were not detected in the sera of 
MCMV-infected mice (161). Neutralizing antibodies were detected by 3 dpi (164).  
Antibodies are not critical to control primary MCMV infections, as high antibody 
titers occur in mice with significant virus titers in organs (161). Nonetheless, 
antibodies are important, as mice depleted of immunoglobulin from birth were 10-fold 
more susceptible to MCMV than normal mice (165). Passive administration of 
neutralizing antibody can restrict virus replication but not the establishment of viral 
latency (164, 166).   
 
1.5.2.2. T cell-mediated immune response 
Cytotoxic T lymphocytes (CTL) are crucial for the clearance of MCMV infected cells 
in BALB/c mice. Adoptive transfer of the CD8 subset of sensitized T lymphocytes 
limited MCMV dissemination, prevented tissue destruction, and protected mice 
against lethal disease (167, 168). Following intraperitoneal MCMV inoculation, CTL 
were found in the spleens of mice from 3 dpi, peaking at 7-8 dpi (82, 169) and active 
until 14 dpi (169).  
Almost 50% of CTL in BALB/c mice are directed against the nonstructural pp89 (IE1) 
protein of the Smith strain (170, 171). Epitope mapping studies have shown that pp89 
contains an immunodominant CD8 T cell epitope, YPHFMPTNL (172, 173). 
IEl-specific CD8 T cells dominate during the acute phase of infection (174). Other 
identified CTL epitopes include those from the m04, M45, and m164 gene products 
(174-176). 
CD4 helper T cells are not absolutely required to initiate CD8 T cell-mediated 
immune responses (167) but are required for viral clearance in certain organs and may 
enhance CD8 T cell responses. In mice depleted of the CD4 subset, clearance of 
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replicating virus occurred in infected tissues except for the salivary glands (177, 178).  
CD4 lymphocytes can compensate for the absence of CD8 lymphocytes (179, 180). 
IFN-γ is required for CD4 T cell activity in the salivary glands (177). CD4 T cells are 
also required for the IgG antibody responses (181).  
 
1.4.3. Immune evasion by MCMV   
Numerous genes of MCMV are responsible for moderating the immune response. 
These genes are generally located at genomic termini, where significant variation 
frequently occurs. The known immune evasion genes are listed in Table 1.2. The 
products of immune evasion genes of MCMV affect various aspects of the immune 
system. The best-studied immune evasion genes are those that subvert NK or T cell 
responses.  
 Table 1.2  MCMV genes associated with immune evasion. 
 
Given the importance of NK cells in suppressing MCMV infection, it is not surprising 
that MCMV encodes numerous proteins that inhibit NK cell function. The viral m152 
product inhibits NK cells by down-regulating the expression of the MHC class I-like 
molecule RAE-1, which is a ligand for the natural killer group 2 D (NKG2D) receptor 
on NK cells (184, 185). NKG2D has two additional activating ligands, mouse 
UL16-binding protein-like transcript 1 (MULT-1) (195) and H60 (196, 197). The 
products of m155 and m145 down-regulate the expression of MULT-1 and H60, 
respectively, and the deletion of these genes from MCMV enhances clearance of the 
Gene Function of product Mechanism  References 
m155 
 
m152 
 
 
 
m145 
 
m144 
 
m138 
m06 
 
m04 
 
inhibits NK cell function  
 
inhibits NK cell function 
 
blocks CTL function 
 
inhibits NK cell function 
 
inhibits NK cell function 
 
avoids ADCC 
blocks CTL function 
 
blocks CTL function 
 
down-regulates H-60, a ligand for the NK cell 
activating receptor NKG2D  
down-regulates RAE-1, a ligand for the NK 
cell activating receptor NKG2D 
retains MHC-I in the endoplasmic reticulum 
(ER)- Golgi intermediate compartment 
down-regulates MULT-1, a ligand for the NK 
cell activating receptor NKG2D 
encodes an MHC-I homolog to inhibit NK cell 
activation 
encodes a viral Fc receptor to avoid ADCC 
down-regulates MHC-I by targeting molecules 
for lysosome degradation 
forms complexes with MHC-I molecules that 
are displayed at the cell surface 
(182, 183) 
 
(184, 185) 
 
(186) 
 
(187) 
 
(188-190) 
(191) 
(192) 
 
(193, 194) 
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virus due to NK cell-specific effects (182, 183, 187). The viral m144 product is a 
homolog of MHC-I molecules that inhibits the NK cell-mediated clearance of MCMV 
in vivo (188). It has been suggested that the m144 protein acts as a decoy for NK cells 
by engaging inhibitory NK cell receptors, although the receptor has not been 
identified yet (188-190).  
Since MHC-I-restricted CD8 T cells are the important effectors during MCMV 
infection, it is understandable that the MHC-I antigen-presentation pathway is 
selected as a major target for immune evasion. Three MCMV gene products alter 
MHC-I function: m152, m06 and m04. The m152 gene product, glycoprotein 40, 
prevents the transport of MHC-I to the cell surface and thereby prevents the 
presentation of MCMV peptides to CD8 T cells (186). The m06 gene encodes 
glycoprotein 48, which interferes with the MHC-I pathway of antigen presentation by 
binding to complexes of MHC-I molecules and antigenic peptides, targeting them for 
degradation in the lysosome (192). The product of m04, glycoprotein 34, binds 
MHC-I in the ER, which interferes with the interaction between MHC-I and the T cell 
receptor (193, 194).  
1.6. Development of vaccines 
With the introduction of regular screening programs for murine pathogens by 
commercial suppliers of laboratory mice and the widespread use of specific 
pathogen-free mice in research, natural MCMV infections in mouse colonies no 
longer occur. While there is no need to develop vaccines to control MCMV infection 
in colonies of laboratory mice, the mouse model has been used to test strategies for 
vaccination against HCMV infection.  
MacDonald et al. (198) demonstrated that subcutaneous immunization with a live 
attenuated MCMV mutant RV7 protected against a lethal challenge with salivary 
gland-passaged wild-type MCMV. They also showed that RV7 was effective when 
administered perorally or intranasally. In addition, it has been shown that 
immunization with plasmid DNA (pDNA) expressing MCMV IE1, m04 and M84 
and/or formalin-inactivated MCMV elicits a strong antibody and cell-mediated 
immunity and provides long-term, complete protection against MCMV infection 
(199-201). 
Development of a vaccine to prevent CMV disease has been identified as a first rank 
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medical priority. Antigens to be targeted by vaccine-induced immune responses have 
been defined. Only a subset of the more than 150 viral proteins is sufficient to induce 
protective immunity. Using this information, strategies for the development of live 
virus vaccines as well as subunit vaccines have been developed. At this point at least 
seven candidate vaccines have been tested clinically, including live, attenuated 
vaccines (Towne and Towne-Toledo recombinants), recombinant gB subunit, 
canarypox vectors, alphavirus replicons, peptides (combination of CD4 and CD8 
T-cell epitopes) and DNA vaccines (202). Although it is still too early to draw firm 
conclusions, some lessons can be extracted from prior work. The most important is 
that a CMV vaccine is feasible, inasmuch as an attenuated and a gB subunit vaccine 
have reduced disease in solid organ transplant recipients. The gB subunit vaccine also 
prevented acquisition of the virus by previously seronegative women. A DNA vaccine 
has reduced viral replication in stem cell transplant recipients. 
 
1.7. Anatomy of nasal and oral cavity of mouse 
Generally, infections upon inoculation via intranasal (without anesthesia) and peroral 
routes mimic natural infection. Since inoculation was done via the oronasal route in 
the present PhD thesis, it is necessary to have a full understanding of the anatomy of 
the nasal and oral cavity of mice.  
 
1.7.1. Nasal cavity    
For all mammalian species, the nose serves as the portal of entry for the air they 
breathe. Mice, unlike humans, are obligate nose breathers, so all inhaled air passes 
through the nasopharynx into the lungs (203). The nasal cavity of mouse is divided 
into two main air passages by the nasal septum. Each nasal passage extends from the 
nostril openings (nares) to the nasopharynx. At the entrance of the nasopharyngeal 
duct, there are the paired aggregates of nasopharynx-associated lymphoid tissue 
(NALT) (Figure 1.9).  
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Figure 1.9  Mouse nasal cavity and anatomic position of NALT. The ventral view of the 
palate is shown with its relative position to the skull. The ellipsoid areas represent the position 
of the NALT in the nasal cavities (204). When the palate is peeled, the paired NALT can be 
observed (arrows).  
In contrast to less than 3% in human nasal cavity, approximately 50% of the mouse 
nasal cavity is lined by olfactory epithelium, demonstrating its important olfactory 
function (Figure 1.10). The olfactory epithelium is a pseudostratified, columnar 
neuroepithelium containing three principal cell types: olfactory neurons, sustentacular 
 
Figure 1.10  Light photomicrograph of a cross-section of the mouse nose (left) and 
immunofluorescence photomicrograph of the olfactory epithelium (right). The olfactory 
neurons are stained with olfactory marker protein (OMP) (red). The unstained epithelial cells 
are of non-olfactory origin.   
 
cells and basal cells. The majority of the non-olfactory nasal epithelium is respiratory 
epithelium. Besides, there are few thin squamous and transitional epithelial cells (203). 
whereby large intraepithelial pockets are formed, which serve
as an initial collection site for transcytosed material.Together
with extensive arrays of intermediate filaments, this pocket
forms the cardinal characteristic of the M cell. Inside the
pocket, lymphocytes as well as macrophages can be found, in
close association with the M-cell membrane, suggestive for
some sort of interaction. Furthermore, M cells form long
basal processes that are found to extend deeper into the lym-
phoid tissue underneath the epithelium, where they can
associate with other cells such as antigen-presenting cells.
Most of the knowledge we have on M cells is based on obser-
vations made in the lymphoepithelium overlying the domes
of Peyer’s patches. However, based on the overall similarities
in structure and occurrence, it is likely that most character-
istics found for Peyer’s patch M cells are attributable to those
in NALT (Fujimura 2000), with perhaps slight regional dif-
ferences, such as binding patterns of lectins. Both rat and
hamster M cells in the NALT stain rather specifically with
GSI-B4, a lectin from Griffonia simplicifolia, directed against
α-linked galactoses (Giannasca et al. 1997; Takata et al.
2000).The importance of these findings may lie in the appli-
cation of such lectins in targeting drugs or vaccines to the
NALT.
M cells seem to be specialized in transcytosis (Kraehen-
buhl and Neutra 2000; Neutra et al. 2001). Bound particles
such as bacteria and viruses induce changes in the apical
membrane and cytoskeleton, after which phagocytosis takes
place. Reorganization of the cell membrane and extension of
cellular processes around the articles have been described,
and the particles are transported through the cell in a hago-
cytic vesicle (Owen 1999). Smaller particles and macromol-
ecules are taken up through clathrin-coated pits or by
receptor-mediated phagocytosis. All material that has been
taken up is released again in the basolateral pocket, but it is
unclear whether any degradation of the transported material
or particles has taken place during the transit and whether
the cells play an active role in antigen presentation.
Nevertheless there seems to be an active interaction between
the M cells and underlying lymphocytes because after deple-
tion of lymphocytes by irradiation the intraepithelial pocket
of the M cells in Peyer’s patches is lost (Ermak et al. 1989).
That the activity of M cells in the NALT is influenced by
antigenic stimuli was found in a comparison of NALT
epithelium from normally reared and specific pathogen-free
(SPF) rats (J ong et al. 2000). First, the number of M cells
was low r and remained lower in SPF rats, but the cells also
showed a more uniform morphology. In conventionally
reared animals, the number of M cells increased with age,
and their morphology altered, leading to extensive cytoplas-
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Fig. 23.1. Anatomic position of nasal-associated lymphoid tissue
(NALT) in the mouse. The ventral view of the palate is shown with its
relative position to the skull. T e ellipsoid areas represent the position
of the NALT in the nasal cavities. Adapted from Heritage et al. 1997.
Fig. 23.2. Histologic position location of the paired conglomerates of
nasal-associated lymphoid tissue (NALT) (arrow) in the nasal cavity
(asterisk) of a BALB/c mouse. (See page 7 of the color plates.)
Hematoxylin-eosin staining. Scale bar: 500 µm. Courtesy of Dr.
Pascale Gueirard (Pasteur Institute, Paris).
Ch023.qxd  10/28/04  2:13 PM  Page 416
30                                                                         Chapter 1   
____________________________________________________________________________________________ 
 
Lymphoepithelium is a specialized epithelium in the nasal airways of mice that covers 
the NALT (203). The overlying lymphoepithelium contains M cells, similar to those 
in gastrointestinal-associated lymphoid tissues (GALT) in the intestines. M cells are 
thought to be involved in the uptake and translocation of inhaled antigens from the 
nasal lumen to the underlying lymphoid tissues. 
The correlate of NALT in humans is the Waldeyer’s Ring, the oropharyngeal 
lymphoid tissues composed of the adenoids and the bilateral tubule, palatine, and 
lingual tonsils. The location of NALT at the entrance of the nasopharyngeal duct is a 
very strategic position because most nasal secretions and inhaled air, presumably 
laden with antigenic material, flow over this area. Although the function of NALT in 
the general mucosal-associated lymphoid system is not fully understood, these 
mucosal lymphoid tissues may play an important role in the regional immune defense 
of the upper airways.  
 
1.6.2. Oral Cavity    
The mouse oral cavity (including the labial, buccal, palatine, and gingival mucosa) is 
lined by variably orthokeratinized squamous epithelium (205). The thickness of the 
keratin layer varies with diet and frequency of ingestion. In contrast, the human oral 
mucosae are composed of nonkeratinized- to slightly parakeratinized-stratified 
squamous epithelium. Unlike human, mice do not have tonsils in the oral cavity.  
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During the past half century, human cytomegalovirus (HCMV) has been recognized 
as a serious viral pathogen in humans. Generally, HCMV causes asymptomatic 
infections in healthy hosts, but in immunocompromised hosts HCMV leads to severe 
manifestations. Currently, little information is available on the natural primary 
infection of HCMV. The entry site upon natural exposure to HCMV has not been well 
known. So far, there is no vaccine available that could prevent HCMV 
infection/reinfection or lessen the burden of HCMV infection and disease. 
Due to the strict species-specificity of cytomegaloviruses (CMV), HCMV cannot be 
studied experimentally in animal models. Therefore, murine cytomegalovirus 
(MCMV) infection in mice has been widely used as a model to study HCMV 
infections in humans. The most commonly used MCMV strain is the Smith strain, 
which has been maintained by either salivary gland passage in laboratory mice or by 
passage in cultured mouse embryonic fibroblast or fibroblastic cell lines. It is possible 
that the Smith strain has acquired significant genetic and biological differences from 
early passages of the Smith isolate. Therefore, there might be doubts on the relevancy 
of using this strain in infection models to extrapolate to HCMV infections in humans. 
MCMV infection in adult mice has been studied with a variety of inoculation routes. 
Most studies have used artificial, usually intraperitoneal, routes of inoculation. So far, 
the question how MCMV replicates in vivo via a natural infection route has not been 
answered.  
Recently, we isolated a new MCMV strain, HaNa1, from M. m. domesticus. Our 
previous studies demonstrated that there were obvious differences in replication 
kinetics in vitro and in vivo between the highly passaged MCMV Smith strain and the 
low-passage HaNa1 strain. Therefore, this thesis aims to generate a better 
understanding of the pathogenesis of natural MCMV infection with the low-passage 
HaNa1 strain upon oronasal inoculation. 
The specific aims of this thesis are: 
1) First, to inoculate oronasally different inbred mouse strains (BALB/c, C57BL/6, 
NOD) with MCMV HaNa1 and to compare the replication kinetics of virus and 
antibody responses in these different mouse strains and to study if the absence of 
functional T cells, B cells and NK cells could increase the susceptibility of 
resistant mice to MCMV replication with NOD.SCID and NSG mice (Chapter 
3). 
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2) Second, to choose the most susceptible mouse strain based on the results of 
Chapter 3 and to inoculate neonatal and adult mice oronasally with MCMV 
HaNa1 to mimic natural primary HCMV infection in healthy infants and adults. 
The virological outcome and antibody response will be analyzed and the entry 
site will be determined (Chapter 4). 
3) Finally, to utilize the established neonatal murine MCMV model to investigate 
whether oronasal inoculation of neonatal mice with an MCMV strain provides a 
protection against an infection with a heterologous MCMV strain in adulthood 
(Chapter 5). 
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Abstract  
At this moment, murine cytomegalovirus (MCMV) infections have been studied 
extensively in inbred mice via the intraperitoneal route of inoculation with highly 
passaged strains. However, the question how a low-passage MCMV replicates in 
inbred mice via a natural route remained unanswered. Here, different inbred mice 
(BALB/c, C57BL/6 and NOD) were inoculated oronasally with a low-passage 
MCMV strain, HaNa1. Viral replication was evaluated by virus titration and 
quantitative real-time PCR, and antibody response was assessed by 
immunoperoxidase cell monolayer assay (IPMA). In BALB/c mice, virus persisted in 
the nasal mucosa (from 3 dpi) and submandibular glands (from 7 dpi) until the end of 
the experiment (49 dpi). In C57BL/6 mice, infectious virus was only detected in nasal 
mucosa from 3 dpi until 21 dpi; viral genome was still detectable in nasal mucosa 
until 49 dpi. Although infectious virus was not detected in submandibular glands of 
C57BL/6 mice, viral genome was detected from 7 dpi until 49 dpi. NOD mice 
appeared to be even more resistant with absence of any productive infection, and viral 
DNA was only detectable at low levels in the nasal mucosa. We demonstrated that 
there was a strong correlation between the degree of productive replication on the one 
hand and the time of first appearance and titer of MCMV-specific IgG antibody on the 
other hand. The deficiency of functional T and B cells and interleukin-2 (IL-2) 
common-γ chain (γc) did not increase the susceptibility to MCMV by the use of 
NOD.SCID and NSG mice. In addition, using monocytic cells from different inbred 
mice we found patterns of resistance similar to those seen in vivo, as assessed by viral 
antigen expression. Taken together, these results demonstrate that upon oronasal 
inoculation, low-passage MCMV HaNa1 replication clearly differs between different 
inbred mice (BALB/c > C57BL/6 > NOD), and that the resistance in vivo to MCMV 
is partly due to the lower susceptibility of the host target cells and is independent of T, 
B cells and γc signaling cytokine-dependent NK cell activities. 
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3.1. Introduction   
During the past fifty years, human cytomegalovirus (HCMV) has been recognized as 
a serious viral pathogen in humans (1, 2). The genetic background and immunological 
status of the host appear to be critical factors in determining the outcome of the 
infection. Generally, HCMV causes asymptomatic infections in healthy hosts, but in 
immunocompromised hosts HCMV leads to severe manifestations. Although recent 
studies in molecular biology have made huge advances in the understanding of 
HCMV replication and gene expression in vitro, in vivo studies have been hindered by 
the strict species specificity.  
The infection of mice with murine cytomegalovirus (MCMV) represents a useful 
model for studying HCMV pathogenesis in primary infection, establishment of 
latency, and reactivation (3). The mouse model is especially attractive because inbred 
strains vary markedly in their susceptibility to an MCMV infection (4-6). The host 
susceptibility to MCMV has been found to be mainly associated with the natural killer 
(NK) cell response, which involves the major histocompatibility complex class I 
(MHC-I, also called H-2 in mice) haplotype background and the Ly49 family of NK 
cell receptors in the NK cell gene complex (NKC) (7). The Ly49 receptors in the 
murine NKC control an effective NK cell response during MCMV infection (8). 
Under normal conditions, inhibitory Ly49 receptors recognize self-MHC-I molecules 
and NK cell activation is prevented. After MCMV infection, MHC-I molecules are 
down-regulated, leaving inhibitory Ly49 receptors unengaged, which results in NK 
cell activation (7). The number of Ly49 haplotypes varies among different mouse 
strains and each mouse strain has a unique MHC-I haplotype. Therefore, the ability to 
mount an effective NK cell response varies among different mouse strains, which may 
have an impact on their susceptibility to an MCMV infection. 
In addition to the genetic background, the virus strain and the route of inoculation also 
influence the response to MCMV infection. Previous studies have utilized highly 
virulent salivary gland-derived virus (SGV), which causes high mortality and a severe  
50                                    Chapter 3 
____________________________________________________________________________________________  
  
pathogenicity in sensitive mouse strains. Similar pathohistological changes can be 
observed even in resistant mouse strains by higher doses of SGV (9). To the best of 
our knowledge, there does not exist any clinical situation of HCMV infection as a 
counterpart to the SGV experimental model (10). MCMV infection in adult mice has 
been studied with a variety of inoculation routes. Most studies have used an artificial, 
usually intraperitoneal route of inoculation. Intraperitoneal inoculation is a systemic 
administration and results in the infection of visceral organs, such as spleen and liver 
as early as two days post inoculation (11). It can be questioned whether infection via 
the i.p. route is optimal to evaluate the resistance of inbred strains to MCMV.   
Recently, we isolated a new MCMV strain, HaNa1, from M. m. domesticus. Our 
previous study demonstrated that there were obvious differences in replication 
kinetics in vitro and in vivo between the highly passaged MCMV Smith strain and the 
low-passage HaNa1 strain (12). In the present study, we inoculated oronasally three 
inbred mouse strains (BALB/c, C57BL/6, NOD) with the low-passage MCMV 
HaNa1 strain and compared the virus replication kinetics and antibody response. We 
also studied the role of functional T cells, B cells and common gamma chain (γc) (the 
cytokine receptor sub-unit that is common to IL-2, -4, -7, -9, -15 and -21) dependent 
NK cells in resistance to MCMV with NOD.SCID (deficiency in functional T and B 
cells) and NSG (deficiency in functional T, B cells and γc) mice. In addition, the 
susceptibility of splenic monocytic cells from BALB/c and C57BL/6 mice to MCMV 
in vitro was compared. 
3.2. Materials and methods 
3.2.1 Mice  
Eight-week-old, female, specific pathogen-free (SPF) BALB/c mice were bred in the 
Faculty of Veterinary Medicine, Ghent University. Eight-week-old, female, SPF 
C57BL/6 mice were purchased from the Janvier Labs. Eight-week-old, male, NOD 
(NOD/ShiLtJ) mice were purchased from Charles River. Eight-week-old, male, 
NOD.SCID (NOD.CB17-Prkdcscid/J) and NSG (NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ) 
mice were provided by the Laboratory of Experimental Immunology, Ghent 
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University. They were all bred under specific-pathogen-free conditions, with food and 
water ad libitum. 
3.2.2 Cell culture and virus 
Primary BALB/c mouse embryonic fibroblasts (MEF) were prepared by 
trypsinization of 16-17 days old fetuses from BALB/c mice and were cultured in 
minimum essential medium (MEM) with 10% fetal calf serum (FCS), 2% lactalbumin 
and a mixture of antibiotics (100 U/ml penicillin, 100 µg/ml streptomycin and 50 
µg/ml gentamicin). The MCMV HaNa1 strain was prepared as previously reported 
(12). The second passage of HaNa1 strain was used for inoculation.   
3.2.3 Inoculation of animal  
Each mouse was inoculated with 100 µl PBS containing 105 TCID50 MCMV HaNa1 
via intranasal (25 µl) and peroral (75 µl) routes without anesthesia. Mice were kept in 
isolation and fed ad libitum. All animal experiments were approved by the Ethical 
Committee of the Faculty of Veterinary Medicine of Ghent University (EC2015/110). 
At various days post inoculation (dpi), mice were sacrificed for collection of samples 
(nasal mucosa, trachea, lungs, submandibular glands, oral mucosa, pharynx, 
esophagus, small intestines, spleen, liver, kidneys).   
3.2.4 Virus titration 
A 10% homogenate was made of all collected tissues for virus titration. Briefly, 
tissues were homogenized using a pestle, a small volume of sterile sand and DPBS 
with 0.9 mM CaCl2, 0.5 mM MgCl2·6H2O and 0.002% phenol red, supplemented 
with 2% FCS and a mixture of antibiotics (100 U/ml penicillin, 100 µg/ml 
streptomycin and 50 µg/ml gentamycin). Afterwards, the supernatants were collected 
after centrifugation (2400×g, 10min). Virus titration was performed on the 
second-passage MEF monolayers. After 7 days, the presence of a cytopathic effect 
(CPE) was assessed by light microscopy (Olympus Optial Co., Hamburg, Germany) 
and virus titer was calculated as 50% TCID50 according to the Reed and Muench 
formula. For those samples which were negative with the above mentioned method, 
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centrifugal enhancement of infection at 1000 × g was applied for 30 min, followed by 
2 h of incubation at 37°C.   
3.2.5 Quantitative real-time (qRT)-PCR   
DNA was extracted from MCMV HaNa1 stock using QIAamp DNA Mini Kit 
(QIAGEN, California, USA) in accordance with the manufacturer's instructions. The 
DNA purity was evaluated using the OD260/OD280 ratio. Primers (forward primer 
5’-GTGCGTTCTTCGTGGAGC-3’; reverse primer 5’-CGCCTTTGTCTACGGTGT 
-3’) were designed in a conserved region of the m152 gene of MCMV HaNa1. They 
were used to amplify the fragment of M152 gene in a 50 µl PCR reaction mixture 
including 10 µl OneTAQ Standard reaction buffer (New England Biolabs Inc., 
Massachusetts, USA), 1 µl dNTP mix, 1 µl forward primer, 1 µl reverse primer, 0.25 
µl OneTAQ DNA-polymerase (New England Biolabs Inc.), 32.75 µl DNase/RNase 
free H2O, and 4 µl DNA. The PCR was performed by an initial incubation at 95 °C 
for 3 min to activate the enzyme with subsequent 35 amplification cycles consisting 
of denaturation at 95 °C for 20 s, annealing at 55 °C for 30 s and extension at 72 °C 
for 2 min. After the final cycle the extension step was prolonged by 10 min at 72 °C 
and subsequently the temperature was lowered to 12 °C. The amplicons were purified 
using the PCR Clean-up kit (Macherey-Nagel, Düren, Germany) and was 
subsequently assessed by sequencing (performed by the GATC Biotech Company, 
Konstanz, Germany). The concentration of DNA was determined by Nanodrop 2000 
system. A quantitation standard curve was achieved by using six 10-fold serial 
dilutions (106-101) of the template DNA with correlation coefficients of 0.9970.  
In order to measure the DNA copy numbers, DNA was extracted from nasal mucosa, 
submandibular glands and PBMC using QIAamp DNA Mini Kit (QIAGEN, 
California, USA) in accordance with the manufacturer's instructions. Assays were 
prepared in 96-well optical reaction plates (Applied Biosystems, Foster City, CA) in a 
total volume of 20 µl including 10 µl PrecisionPLUS 2×qPCR MasterMix with SYBR 
Green and ROX (PrimerDesign Ltd., Southampton, UK), 50 nM forward primer 
5’-GTGCGTTCTTCGTGGAGC-3’, 50 nM reverse primer 5’-CGCCTTTGTCTACG 
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GTGT-3’, 6.8 µl LiChrosolv water, and 3 µl sample DNA or diluted DNA standard. 
The thermal cycling conditions were an enzyme activation at 95 °C for 2 min, and 
then 40 cycles of each 15 s at 95 °C and 60 s at 60 °C. A first-derivative melting 
curve analysis was performed by heating the mixture to 95 °C for 15 s, then cooling to 
60 °C for 1 min, and heating back to 95 °C at 0.3 °C increments. Quantitative PCR 
was performed in a 7700 ABI Prism Sequence Detector (Applied Biosystems, Life 
Technologies Corporation, Carlsbad, CA, USA). Each sample was measured twice 
and the average concentration was used. 
3.2.6 Determination of MCMV-specific antibodies  
The antibody titer of MCMV-specific antibodies was determined by an in-house 
developed immunoperoxidase cell monolayer assay (IPMA) as previously published 
(12). Briefly, twofold dilutions of heat-inactivated plasma (56°C water-bath, 30 min), 
starting with an initial dilution of 1:16 in PBS-Tween with 10% normal goat serum, 
were added to fixed monolayers of MEF infected with MCMV in 96-well plates and 
incubated at 37 °C for 1 h, followed by a thorough washing. Biotinylated rat 
anti-mouse IgM (eBioscience, 1:100) or biotinylated sheep anti-mouse IgG (GE 
healthcare, 1:200) was added to the plates and incubated at 37 °C for 1 h. After three 
washes, streptavidin-biotin horseradish peroxidase complex (GE, 1:200) were added 
to the wells and incubated at 37 °C for 1 h. Finally, NaAc-AEC-H2O2 was added into 
each well at room temperature for 30 min and then the reaction was stopped with PBS. 
The IPMA titer was calculated as the reciprocal value of the highest plasma dilution 
that gives a visual staining of infected MEF, as determined by light microscopy. 
3.2.7 Isolation and infection of splenic monocytic cells in vitro 
Single-cell suspensions of spleens of adult BALB/c and C57BL/6 mice were prepared. 
Briefly, spleens were cut into small pieces and then the tissues were filtered through a 
100 µm Nylon cell strainer. Cell pellets were collected by centrifugation at 300 × g at 
4°C for 10 min and then resuspended in red blood cell lytic buffer on ice for 3 
minutes. Lysis was stopped by diluting the lytic buffer with 10 times volume of PBS. 
Next, cell pellets were collected by centrifuge at 300 × g at 4°C for 10 min and then 
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resuspended in RPMI supplemented with 5% fetal calf serum, 100 U/ml penicillin, 
100 µg/ml streptomycin and 50 µg/ml gentamycin. Afterwards, cells were seeded in 
24-well plates and cultivated at 37°C with 5% CO2. After 24 h, suspending cells were 
removed. 
Adherent cells were identified with monocytic cell markers (CD11b and F4/80) and 
more than 90% cells were monocytic cell. Adherent cells (1×105) were inoculated 
with MCMV HaNa1 strain at a multiplicity of infection (MOI) of 10 in 200 µl 
medium at 37 °C for 1 h with 5% CO2. Then cells were gently washed twice with 
RPMI to remove the inoculum and further incubated with fresh medium. Mock 
inoculation was carried out in parallel. At 1, 3, 6, 12, 24, 36, 48, 72 hours post 
inoculation (hpi), cells were collected for immunofluorescence staining. 
3.2.8 Immunofluorescence staining 
Viral antigen positive cells were detected by an immunofluorescence staining. Cells 
were fixed in 100 % methanol at -20°C for 10 min and then incubated at 37 °C for 1 h 
with mouse anti-MCMV IE1, anti-MCMV E1 and anti-MCMV gB monoclonal 
antibodies (Capri, Croatia), respectively. Subsequently, samples were incubated at 
37 °C for 1 h with FITC-conjugated goat anti-mouse IgG. The nuclei were 
counterstained with Hoechst 33342 at 37 °C for 10 min. Fluorescence was visualized 
using a Leica TCS SP2 confocal microscope. The percentage of viral antigen-positive 
cells was calculated. 
3.3. Results  
3.3.1 Kinetics of MCMV replication in various tissues of BALB/c, C57BL/6, NOD, 
NOD.SCID, NSG mice 
Infectious virus titers were determined in various tissues by virus titration. After 
oronasal inoculation of 105 TCID50 MCMV HaNa1 per mouse, viral replication 
started in the nasal mucosa of BALB/c mice (Figure 3.1), and virus titers rapidly 
increased reaching a plateau at 5, 7, 10 dpi, slightly decreased at 14 dpi and gradually 
increased reaching the highest titer (104.5 TCID50) at the end of the experiment (49 
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dpi). In C57BL/6 mice, viral replication also started in the nasal mucosa at 3 dpi 
(Figure 3.1), but persisted only till 21 dpi. Compared to BALB/c mice, virus titers 
 
Figure 3.1.  Virus titers of MCMV HaNa1 in the nasal mucosa of BALB/c, C57BL/6, NOD, 
NOD.SCID and NSG mice following oronasal inoculation with 105 TCID50 MCMV HaNa1. 
For each time point, the each value and the mean of virus titers from 3-4 mice are shown. The 
detection limit of the titration assay is shown as a dotted line. Statistical analyses were 
performed using an unpaired t test. *, P < 0.05; **, P < 0.005.  
in nasal mucosa of C57BL/6 were 10-100 fold lower at most time points. In NOD, 
NOD.SCID, NSG mice, infectious virus was not detected in nasal mucosa throughout 
the experiment. Virus replication was detected in the submandibular glands of 
BALB/c mice from 7 dpi till 49dpi, but not in the submandibular glands of C57BL/6, 
NOD, NOD.SCID and NSG mice (Figure 3.2). Virus was transiently detected in lungs 
of only BALB/c mice (1 out of 3 mice) at 5 dpi. Overall, infectious virus was not 
detected in trachea, oral mucosa, pharynx, esophagus, small intestines, spleen, liver, 
kidneys of all infected mice strains at any time point (data not shown).   
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3.3.2 Detection and quantification of MCMV DNA in various tissues of different 
mouse strains 
We next assessed the MCMV DNA loads in the nasal mucosa and submandibular 
glands of each infected mouse using qRT-PCR. In the nasal mucosa of BALB/c mice, 
the DNA load was 103.5 copies/g tissues at 3 dpi, afterwards it increased and formed a  
 
Figure 3.2.  Virus titers of MCMV HaNa1 in the submandibular glands of BALB/c, 
C57BL/6, NOD, NOD.SCID and NSG mice following oronasal inoculation with 105 TCID50 
MCMV HaNa1. For each time point, the each value and the mean of virus titers from 3-4 
mice are shown. The detection limit of the titration assay is shown as a dotted line.  
platform at 105 copies/g tissues from 5 dpi till 49 dpi (Figure 3.3). In contrast, the 
DNA load was approximately 10-fold lower in the nasal mucosa of C57BL/6 mice 
(Figure 3.3). In the nasal mucosa of NOD, NOD.SCID and NSG mice, infectious 
virus was not detected, but low-level DNA loads (~103.5 copies/g) were detected at 7, 
28 and 56 dpi (Figure 3.3). In the submandibular glands of BALB/c mice, the DNA 
load was detected at 7 dpi with 104.4 copies/g tissue. Afterwards, it increased to 
106-107 copies/g tissue from 10 dpi till the end of the experiment (49 dpi) (Figure 3.4). 
In the submandibular glands of C57BL/6 mice, DNA was detected from 7 dpi but the 
DNA load was 1000-fold less than that of BALB/c mice from 10 dpi till 49 dpi 
(Figure 3.4). In NOD mice, almost no DNA was detected on the three time points 
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(Figure 3.4). In NOD.SCID mice, a low-level DNA load (~103.5 copies/g) was 
detected in 2 out of 4 mice only at 56 dpi (Figure 3.4). In NSG mice, a low-level 
DNA load (~103.5 copies/g) was detected in one out of four mice at 28 dpi and in 3 out 
of 4 mice at 56 dpi (Figure 3.4).  
 
 
Figure 3.3.  Number of MCMV genome copies assayed by qRT-PCR in the nasal mucosa of 
BALB/c, C57BL/6, NOD, NOD.SCID and NSG mice following oronasal inoculation with 105 
TCID50 MCMV HaNa1. Each value and mean are shown. The detection limit for the 
qRT-PCR assay is shown as a dotted line. 
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Figure 3.4.  Number of MCMV genome copies assayed by qRT-PCR in the submandibular 
glands of BALB/c, C57BL/6, NOD, NOD.SCID and NSG mice following oronasal 
inoculation with 105 TCID50 MCMV HaNa1. Each value and mean are shown. The detection 
limit of the qRT-PCR assay is shown as a dotted line.  
3.3.3 Kinetics of antibody response of different mouse strains during primary MCMV 
infection  
An IPMA was used to determine the total anti-MCMV IgM and IgG antibodies in 
plasma of all infected mice strains (Figure 3.5). After primary infection with MCMV 
HaNa1, MCMV-specific IgM antibodies were not found in any of the infected mouse 
strains during the course of the experiment. MCMV-specific IgG antibodies were 
detected as early as 10 dpi in BALB/c mice, while no MCMV-specific IgG antibodies 
were detected in C57BL/6 mice until 14 dpi. Afterwards, titers increased rapidly in 
BALB/c mice and reached a maximal level (1:2048) at 35 dpi, but rose slowly in 
C57BL/6 mice with a peak (1:258) at 35 dpi. In NOD mice, lower amounts of 
MCMV-specific IgG antibodies were detected at 28 dpi (1:32-1:64) and 56 dpi (1:32). 
In NOD.SCID and NSG mice, MCMV-specific IgG antibodies were not demonstrated 
at the three given time points. 
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Figure 3.5.  Curves of MCMV specific IgG antibody titers assayed by IPMA in infected 
BALB/c, C57BL/6, NOD, NOD.SCID and NSG mice following oronasal inoculation with 105 
TCID50 MCMV HaNa1. For each value, mean and SD of the antibody titers of 3-4 mice are 
shown. The detection limit of the IPMA is shown as a dotted line. 
3.3.4 Replication kinetics of MCMV in splenic monocytic cells of different mouse 
strains in vitro 
In addition to studies in vivo, the ability of MCMV replication was examined in 
splenic monocytic cells of BALB/c and C57BL/6 mice in vitro. The expression 
kinetics of the three major classes of proteins (IE1, E1, gB) at 1, 3, 6, 12, 24, 36, 48, 
72 hpi were evaluated by indirect immunofluorescence staining (Figure 3.6).  
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Figure 3.6.  Expression kinetics of MCMV proteins in splenic monocytic cells of BALB/c 
and C57BL/6 mice. Immunofluorescence stainings of immediate-early (IE1), early (E1) and 
late (gB) proteins were performed in triplicate and data are represented as means ± SD. 
Statistical analyses were performed using a paired t test. Bar, 10 µm.  
In MCMV-inoculated monocytic cells of BALB/c mice, IE protein was detected in 
the nuclei of 0.83 % of cells as early as 3 hpi and E1 protein was detected in the nuclei 
of 0.21% of cells as early as 6 hpi. The number of positive cells for the two viral 
proteins increased over time. A maximum of 1.30% of IE1-positive cells was reached 
at 36 hpi and a maximum of 0.3% of E1-positive cells was reached at 24 and 36 hpi. 
The late gB started to appear in the cytoplasm of 0.19% of the cells from 36 hpi. 
Afterwards, the percentage of IE1-positive and E1-positive cells decreased gradually 
and the percentage of gB-positive cells did not increase. At 72 hpi, the IE protein was 
expressed in 1.10 % of cells, the E1 protein was detected in 0.23 % of cells and the late 
gB was found to be expressed in 0.18 % of cells.    
In MCMV-inoculated monocytic cells of C57BL/6 mice, IE protein was detected in 
1 3 6 12 24 36 48 72
0.0
0.3
0.6
0.9
1.2
1.5
hpi
M
CM
V-
ino
cu
lat
ed
 ce
lls 
ex
pre
ssi
ng
 pr
ote
in 
(%
)
BALB/c
IE1
E1
gB
1 3 6 12 24 36 48 72
0.0
0.3
0.6
0.9
1.2
1.5
hpi
M
CM
V-
ino
cu
lat
ed
 ce
lls 
ex
pre
ssi
ng
 pr
ote
in 
(%
)
C57BL/6
IE1
E1
gB
MCMV             Hoechst              Merge?
IE1?
E1?
gB?
MCMV             Hoechst              Merge?
IE1?
E1?
gB?
Chapter 3: Difference in replication of MCMV in BALB/c, C57BL/6 and NOD mice  61 
____________________________________________________________________________________________ 
 
 
the nuclei of 0.05 % of cells as early as 3 hpi and E1 protein was detected in the nuclei 
of 0.02% of cells as early as 6 hpi (Figure 3.6). The number of positive cells for the 
two viral proteins increased over time. A maximum of 0.14% of IE1-positive cells 
and of 0.07% of E1-positive cells was reached at 36 hpi. The late protein gB started to 
appear in the cytoplasm of 0.05% of the cells from 36 hpi. At 36 hpi, the percentages 
of IE1, E1, gB-positive cells were 9-fold, 4-fold, 4-fold lower compared with those of 
BALB/c mice, respectively. Afterwards, the percentages of IE1, E1, gB-positive cells 
decreased gradually till 72 hpi. At 72 hpi, the IE protein was expressed in 0.09 % of 
cells, the E1 protein was detected in 0.05 % of cells and the late gB was found to be 
expressed in 0.03 % of cells. 
Statistical analyses were performed using a paired t test and significant differences 
were found between IE (P = 0.0003), E1 (P = 0.0009) and gB (P = 0.0001) of two 
mouse strains. 
4. Discussion   
In the present study, we followed the replication kinetics of MCMV HaNa1 in adult 
BALB/c, C57BL/6 and NOD mice upon oronasal inoculation. In BALB/c mice, a 
persistent infection was detected in nasal mucosa (from 3 dpi) and submandibular 
glands (from 7 dpi) till the end of experiment (49 dpi). At 14 dpi the virus titer in the 
nasal mucosa temporarily decreased, which might be due to the appearance of 
adaptive immune responses, but afterwards the replication was not restricted. 
C57BL/6 mice showed a more restricted MCMV replication. It was strongly reduced 
in the nasal mucosa and was even blocked in the submandibular glands. In NOD mice, 
infectious virus was even not detected in the nasal mucosa and submandibular glands. 
Therefore, NOD mice appear to be even more resistant to MCMV HaNa1 than 
C57BL/6 upon oronasal inoculation. There was a clear correlation between the extent 
of virus replication and the serum antibody response. The NOD mice produced lower 
levels of IgG antibody titers than BALB/c and C57BL/6 mice.  
The degree of MCMV replication varies among the different inbred mice. It can be 
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attributed to intrinsic factors of target cells on the one hand and immunological 
responses on the other hand. In the present study, we compared the replication 
kinetics of MCMV in splenic monocytic cells, which have been shown to be one of 
the carrier cells in MCMV systemic dissemination (13), from BALB/c and C57BL/6 
mice. It was found that splenic monocytic cells of BALB/c mice are more sensitive to 
the MCMV infection than those of C57BL/6 mice, which is consistent with other 
studies using non-target cells, such as MEF and peritoneal macrophages (14, 15). 
Replication difference in cells from different mouse strains might be attributed to 
some cellular intrinsic factors, e.g. receptor-related issues (numbers and 
configuration), interference phenomenon and activities of histone acetylases/ 
deacetylases. Identifying these cellular factors is the object of future research.  
Besides the cellular intrinsic factors, previous studies have shown that murine 
susceptibility to MCMV is associated with the NK cell response, which involves the 
self-MHC-I haplotype and the Ly49 family of NK cell receptors (7). The number of 
Ly49 haplotypes varies a lot among strains (8). Each mouse strain has a unique 
MHC-I haplotype. Therefore, the ability to mount an effective NK cell response 
varies among different mouse strains, which may impact on their susceptibility to an 
MCMV infection. Ly49 receptors also recognize MHC-I-like proteins on the infected 
cells. It is well known that the product of the Ly49H gene mediates the activation of 
NK cell by the binding of Ly49H on the surface of NK cells to an MCMV-encoded 
MHC-I homologue, m157 protein (16, 17). Therefore, Ly49H- mice (e.g. BALB/c) 
may show increased virus titers in tissues than Ly49H+ mice (e.g. C57BL/6, NOD) 
during MCMV infection.  
Interestingly, the results from the present study are clearly different from those in 
previous reports with highly virulent SGV of MCMV inoculated via the 
intraperitoneal route. In BALB/c mice, infection with MCMV SGV results in an 
extensive multi-organ replication (9). Although there is a trend towards relatively 
lower virus titers in the tissues of resistant C57BL/6 and NOD mice compared with 
susceptible BALB/c mice, a multi-organ infection could still be observed in C57BL/6 
Chapter 3: Difference in replication of MCMV in BALB/c, C57BL/6 and NOD mice  63 
____________________________________________________________________________________________ 
 
 
and NOD mice (18, 19). Furthermore, there is no correlation between the virus titer 
reached in the target organs and the time of onset and titers of IgG antibody produced 
among different inbred mouse strains (4). In our model (HaNa1, oronasal inoculation), 
replication differences between mouse strains were much more pronounced. 
Differences in replication power might be partly attributed to genomic differences 
between highly passaged strains and low-passage MCMV strains. MCMV has several 
immuno-evasion genes, e.g. m157, m152, m144, m138, m04, whose products mediate 
the antiviral NK cell response (20). We have compared these genes between HaNa1 
and two laboratory strains, Smith and K181 (Table 3.1). Among these genes, the 
m144 and m157 gene of HaNa1 have nucleotide differences when compared to the 
Smith and K181 strains, leading to 8% and 9% amino acid changes. The m144 and 
m157 gene products serve as MHC-I homologues, whose recognition by inhibitory 
NK cell receptors during infection (e.g. Ly49I) can potentially prevent NK-cell 
activation and target cell killing (17, 21-23). These gene variations might be in part 
responsible for the different replication kinetics in genetically resistant mouse strains 
with different MCMV strains.  
Table 3.1. Nucleic/amino acid identities of genes/gene products involved in NK cell response 
between MCMV HaNa1 and two other MCMV strains by NCBI BLAST. 
In order to investigate whether immunodeficiency can increase the susceptibility of 
genetically resistant mice to MCMV, we inoculated the NOD.SCID and NSG mice 
oronasally with MCMV HaNa1. NOD.SCID mice are characterized by an absence of 
functional T and B cells. NSG mice combine the features of the NOD.SCID mice, 
with that of IL-2 common-γ chain (γc) deficiency. Due to the deficiency of γc (the 
common cytokine receptor for IL-2, -4, -7, -9, -15 and -21), NSG mice are supposed 
to be deficient in NK cell activity and more immunodeficient than NOD.SCID mice 
Genes of MCMV HaNa1 
(accession number) 
Nucleic acid identity (%) Amino acid identity (%) 
MCMV Smith  MCMV K181  MCMV Smith MCMV K181 
m157 (KT289520) 96 96 91 91 
m152 (KR184673) 99 99 98 98 
m144 (KR184672) 95 94 92 92 
m138 (KR184671) 99 99 99 98 
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(24, 25). However, in the present study infectious virus was not detected in 
NOD.SCID mice, which indicates that in genetically resistant mice deficiency of 
mature T and B cells does not increase the susceptibility to MCMV. Surprisingly, the 
deficiency of γc does not increase the susceptibility to MCMV either. A possible 
explanation is that NK cells are activated via a non-γc dependent mechanism. Sun, et 
al. (26) have demonstrated that during an MCMV Smith infection in Il15−/− × 
Il15ra−/− and Rag2−/− × Il2rg−/− C57BL/6 (Ly49H+) mice, activation and proliferation 
of NK cells are independent from IL-15 or other γc signaling cytokines, but 
unfortunately they did not evaluate MCMV replication. In fact, NK cells undergo two 
distinct phases of activation during MCMV infection in genetically resistant mouse 
strains (27, 28): a nonselective phase mediated by proinflammatory cytokines and a 
specific phase driven by viral proteins. In the nonselective phase, IL-12 might play an 
important role in NK cell production of IFN-γ and NK cell blastogenesis during 
MCMV infection (29, 30). In the specific phase, viral ligands, such as m157 and m04, 
are driving the NK cell response. 
In the present work, a productive infection was not detected in submandibular glands 
of C57BL/6 and nasal mucosa and submandibular glands of NOD, NOD.SCID and 
NSG mice, but the viral genome could be detected in nasal mucosa and 
submandibular glands of these resistant mice at certain time points. Therefore, latency 
might have been established in these tissues. In submandibular glands of C57BL/6, 
viral genome but no infectious virus was found from 7 dpi, which demonstrates viral 
spread to this site. It is likely that virus might already be latent before disseminating to 
the acinar epithelial cells, the productive replication site of MCMV in submandibular 
glands. Reddehase et al. have suggested that a cell type different from the acinar 
epithelial cells can be the cellular site of latency in submandibular glands (31). While 
latency occured in submandibular glands, virus replication still persisted in the nasal 
mucosa of C57BL/6 mice from 3 dpi till 21 dpi. This phenomenon was also observed 
by Kurz et al. who indicated that molecular latency can be established in one organ, 
while productive infection continues in another organ (32). In more resistant NOD 
mice, latency seems to be more easily and earlier established than in C57BL/6 mice, 
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not only in submandibular glands but also in nasal mucosa. Our previous study 
showed that in the nasal mucosa the infected cells were identified as olfactory neurons 
and sustentacular cells in olfactory epithelium and macrophages and dendritic cells in 
NALT (12). In genetically resistant mice, the cellular site of molecular latency 
remains unknown.   
In summary, it was shown by using oronasal inoculation with low-passage MCMV 
HaNa1 that virus replication clearly differs between different inbred mice (BALB/c > 
C57BL/6 > NOD); resistance in vivo to MCMV is partly due to a lower susceptibility 
of host target cells and is independent of T, B cells and γc signaling 
cytokine-dependent NK cell activities. 
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Abstract 
In healthy individuals, naturally acquired infections of human cytomegalovirus 
(HCMV) are generally asymptomatic. Animal models mimicking the natural primary 
HCMV infections in infants and adults are scarce. Here, neonatal and adult BALB/c 
mice were inoculated oronasally with a Belgian isolate HaNa1 of murine 
cytomegalovirus (MCMV). None of the mice showed clinical symptoms. In neonatal 
mice, a typical systemic infection occurred. In adult mice, viral replication was 
restricted to the nasal mucosa and submandibular glands. Infectious virus was not 
detected in trachea, oral mucosa, pharynx, esophagus, small intestines of both 
neonatal and adult mice at any time point. The nose was demonstrated to be the entry 
site. Double immunofluorescence staining showed that the infected cells in the nose 
were olfactory neurons and sustentacular cells in the olfactory epithelium and were 
macrophages and dendritic cells in nasopharynx-associated lymphoid tissues (NALT). 
Neonatal and adult mice developed a similar antibody response pattern, though the 
magnitude in neonatal mice was lower. In summary, we have established intranasal 
infections (without anesthesia) of neonatal and adult mice with murine CMV HaNa1, 
which mimic the range and extent of virus replication during natural primary HCMV 
infections in healthy infants and adults. These findings bring new insights in the 
pathogenesis of natural primary CMV infections.   
 
Chapter 4: Difference in replication of MCMV HaNa1 in neonatal and adult BALB/c mice  71 
____________________________________________________________________________________________ 
 
 
 
4.1. Introduction 
In general, primary infection of human cytomegalovirus (HCMV) is asymptomatic in 
healthy infants and adults. Therefore little information is currently available on the 
natural primary infection of HCMV (1). The earliest phase of cytomegalovirus 
infection has not been studied well in humans or experimental animal models. 
Following natural community exposure to HCMV, the entry site has not been 
discovered (2). Due to the strict species-specificity of cytomegaloviruses (CMV), 
HCMV cannot be studied experimentally in animal models.  
In vivo studies of HCMV are generally modeled using murine cytomegalovirus 
(MCMV) in mice (3). The most commonly used MCMV strain is the Smith strain, 
which has been maintained by either salivary gland passage in laboratory mice or by 
passage in cultured mouse embryonic fibroblast or fibroblastic cell lines (3). It is 
possible that the Smith strain has acquired significant genetic and biological 
differences from early passages of the Smith isolate (4). Therefore, there might be 
doubts on the relevancy of using this strain in infection models to extrapolate obtained 
data to HCMV infections in humans. For HCMV it has been demonstrated that 
extensively passaged laboratory strains show significant biological differences 
compared to low-passage clinical isolates (5). Therefore, the use of low-passage 
isolates is necessary and measures should be taken to avoid adaptation.  
In addition, the pathogenesis of MCMV has been studied using a variety of routes of 
inoculation (3), e.g. intraperitoneal, intranasal (with anesthesia), footpad. So far, the 
question how MCMV replicates in vivo via a natural infection route has not been 
answered. Infections requiring injection or anesthesia cannot be considered as natural. 
Generally, intranasal and oral routes without anesthesia are widely accepted as the 
natural infection routes.  
Recently, we isolated a new MCMV isolate, HaNa1, from Mus musculus. Partial gene 
sequences have been submitted to GenBank (accession number: KR184668 (m06 
gene), KR184669 (m033 gene), KR184670 (MCK2 gene), KR184671 (m138 gene), 
KR184672 (m144 gene), KR184673 (m152 gene), KT289520 (m157 gene)). Our 
previous study demonstrated that in vitro MCMV HaNa1 grew to a ~10-fold lower 
yield in comparison with the MCMV Smith strain in mouse embryonic fibroblasts 
(MEF) and that MCMV HaNa1 was more cell-associated than MCMV Smith (6). In 
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vivo, MCMV HaNa1 reached higher titers in the nasal mucosa and submandibular 
glands than MCMV Smith. Only the Smith strain established productive infections in 
the spleen, liver and kidneys of adult mice. In the present study, neonatal and adult 
mice were experimentally inoculated with MCMV HaNa1 oronasally, and the 
virological outcome and antibody response were analyzed. 
4.2. Materials and methods 
4.2.1. Cell culture and virus   
Primary BALB/c MEF were prepared by trypsin digestion of 16 - 17 days old fetuses 
from BALB/c mice and were cultured in minimum essential medium (MEM) with  
10% fetal calf serum (FCS), 2% lactalbumin and a mixture of antibiotics (100 U/ml 
penicillin, 100 µg/ml streptomycin and 50 µg/ml gentamicin). The MCMV HaNa1 
isolate was originally isolated with secondary MEF from the nasal mucosa of a mouse 
(M. musculus), caught alive in Belgium. Subsequently, it was passaged on secondary 
MEF to produce viral stocks. The second passage of the HaNa1 isolate was used for 
inoculation.    
4.2.2. Inoculation of mice 
Specific pathogen-free (SPF) BALB/c mice were provided by the Faculty of 
Veterinary Medicine of Ghent University. Female BALB/c mice were inoculated at 
the age of 3 days (neonates) or 8 weeks (adults). For the inoculation of adults, 105 
TCID50 MCMV HaNa1 in 100 µl PBS was pipetted into the nares (25 µl) and mouth 
(75 µl) without anesthesia. For the inoculation of neonatal mice, 105 TCID50 MCMV 
HaNa1 in 10 µl PBS was pipetted into the nares (2.5 µl) and mouth (7.5 µl) without 
anesthesia. All animal experiments were approved by the Ethical Committee of the 
Faculty of Veterinary Medicine of Ghent University.  
4.2.3. Virological analysis 
At various days post inoculation (dpi), mice were sacrificed for collection of tissues 
and blood. Tenfold dilutions of 10% homogenates were brought onto monolayers of 
secondary MEF for 1 h at 37°C and afterwards cells were washed and followed for 
the presence of cytopathic effect. After 7 days, the virus titer was calculated as 50% 
tissue culture infectious dose (TCID50), according to the Reed and Muench formula. 
Peripheral blood mononuclear cells (PBMC) were isolated as previously published  
(6) and cocultured with MEF monolayers to examine cell-associated viremia.  
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4.2.4. Immunofluorescence staining 
The detection of viral antigen positive cells in tissues was done by an 
immunofluorescence staining. Cryosections of 12 µm were fixed in 4% 
paraformaldehyde at 4 °C for 10 min, followed by permeabilization in 0.1% Triton 
X-100. Samples were incubated with biotinylated mouse anti-MCMV polyclonal 
antibodies (pAb) at 37 °C for 1 h. Then, samples were thoroughly washed and 
incubated with fluorescein isothiocyanate (FITC) conjugated streptavidin (Invitrogen, 
1:200) at 37 °C for 1 h. After 3 further washes in PBS, the nuclei were counterstained 
with Hoechst. Fluorescence was visualized using a Leica TCS SP2 confocal 
microscope and analyzed with ImageJ. 
MCMV antigen-positive cells were quantified with the Leica TCS SP2 confocal 
microscope (magnification 200 ×) according to the previous quantification method (6). 
Twenty consecutive sections of 12 µm were analyzed per organ. The size of the 
sections was determined by the number and size of the visual fields at 200 × 
magnification. Finally, the number of MCMV antigen-positive cells was calculated as 
an average value per 10 mm2, independent of their localization and distribution within 
the section.  
4.2.5. Double immunofluorescence staining 
Double immunofluorescence staining was used to identify MCMV-infected cells in 
the nasal mucosa and NALT. Sections were incubated with biotinylated mouse 
anti-MCMV polyclonal antibodies (pAb) and cell markers (goat anti-olfactory marker 
protein (OMP) for olfactory neurons, 1:500 (Wako); rabbit polyclonal 
anti-cytokeratin-18 for epithelia, 1:150 (Abcam); rat anti-mouse CD68 for tissue 
macrophages, 1:50 (eBioscience) and hamster anti-mouse CD11c for dendritic cells, 
1:50 (eBioscience)) at 37 °C for 1 h. The sections were washed three times with PBS 
and incubated at 37 °C for 1h with the corresponding secondary antibodies: 
streptavidin-Texas Red-X or FITC conjugate, 1:200 (Invitrogen); 
FITC-goat-anti-rabbit IgG, 1:200 (Invitrogen); Alexa Fluor® 594-rabbit-anti-goat IgG, 
1:200 (Invitrogen); Alexa Fluor® 488-goat-anti-rat IgG, 1:200 (Invitrogen); Alexa 
Fluor® 488-goat-anti-hamster IgG, 1:200 (Jackson ImmunoResearch). After 3 further 
washes in PBS, the nuclei were counterstained with Hoechst. Fluorescence was 
visualized using a Leica TCS SP2 confocal microscope and analyzed with ImageJ. 
74              Chapter 4 
____________________________________________________________________________________________ 
 
4.2.6. MCMV-specific antibody titers determined by immunoperoxidase cell 
monolayer assay (IPMA) 
The antibody titer of MCMV-specific antibodies was determined by an in-house 
developed IPMA as previously published (6). Briefly, twofold dilutions of inactived 
plasma, starting with an initial dilution of 1:16 in PBS-Tween with 10% normal goat 
serum, were added to fixed monolayers of MEF infected with MCMV HaNa1 in 
96-well plates and incubated at 37 °C for 1 h, followed by a thorough washing. 
Biotinylated rat anti-mouse IgM (eBioscience, 1:100), biotinylated sheep anti-mouse 
IgG (GE healthcare, 1:200), biotinylated rat anti-mouse IgG1 (eBioscience, 1:100), 
biotinylated rat anti-mouse IgG2a (eBioscience, 1:100), biotinylated rat anti-mouse 
IgG2b (Biolegend, 1:100), biotinylated goat anti-mouse IgG2c (Abcam, 1:100), or 
biotinylated rat anti-mouse IgG3 (Biolegend, 1:100) were added to the plates and 
incubated at 37 °C for 1 h. After three washes, streptavidin-biotin horseradish 
peroxidase complex (GE, 1:200) was added to the wells and incubated at 37 °C for 1 
h. Finally, NaAc-AEC-H2O2 was added into each well at room temperature (RT) for 
30 min and then the reaction was stopped with PBS. The IPMA titer was calculated as 
the reciprocal value of the highest plasma dilution that gives a visual staining of 
infected MEF, as determined by light microscopy.    
4.2.7. Virus neutralization assay 
Neutralizing antibody titers were determined in a virus neutralization assay. Twofold 
dilutions of inactivated plasma were mixed with 100 TCID50 MCMV HaNa1 and 
incubated at 37°C for 1 h. The mixture was then added to MEF monolayers and 
incubated at 37°C for 1 h. The cells were then washed, overlaid with fresh medium, 
and incubated at 37°C for 7 days. The neutralizing titers can be defined as the 
reciprocal of the highest dilution of plasma preventing 100% cytopathic effect in MEF 
cell cultures. 
4.2.8. Determination of IgG avidity 
IgG avidity was determined by a published protocol (7) with small modifications. 
Briefly, plasma was diluted 1:100 in BSA-PBS-Tween. Following incubation and 
removal of the diluted plasma, the wells were incubated for 5 min with 8 M urea or 
PBS. The wells were subsequently washed and goat anti-mouse IgG-peroxidase 
antibody (Sigma) (1:10000) was added to the wells. After incubation and washing, the 
substrate (TMB) (R&D Systems) was added and 30 min later the concentration of the 
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IgG was measured by determining the absorbance with an ELISA reader (Thermo) at 
450 nm. The avidity index (AI) was calculated as the mean absorbance of reactions 
exposed to urea divided by that exposed to PBS, expressed as a percentage. The AI 
results were interpreted as follows: AI of <50% = low-avidity or moderate-avidity 
antibodies; 50 -100% = high-avidity antibodies. 
4.2.9. Statistical analysis   
Data from experimental groups were compared using student t test by Prism 6 
software (GraphPad, San Diego, CA). Differences were statistically significant when 
P < 0.05. 
4.3. Results 
4.3.1. Kinetics of virus replication in various tissues 
None of the inoculated mice showed clinical signs. Virus titration results are 
represented in Figure 4.1. For neonates and adults, viral replication occurred in the 
nasal mucosa from 3 dpi till the end of the experiment (49 dpi). Afterwards, virus 
replication was detected in lungs of neonates from 5 dpi to 17 dpi. In contrast, only at 
5 dpi virus was transiently detected in lungs of adults. Virus replication was detected 
in the submandibular glands from 7 dpi. Only in neonatal mice, virus replication also 
occurred in multiple internal organs such as spleen, kidneys and brains. Infectious 
virus was not detected in trachea, oral mucosa, pharynx, esophagus, small intestines, 
and plasma of either neonatal or adult mice at any time point (data not shown). 
Coculture showed that at 7 dpi, infectious virus was recovered from PBMC of adult 
mice. Due to the limited volume of blood from neonatal mice, it was not possible to 
extract PBMC from neonatal mice for coculture.  
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Figure 4.1.  Virus titers of MCMV HaNa1 in the nasal mucosa, lungs, submandibular glands, 
spleen, kidneys, brains of neonatal mice (3 days old) (left side) and adult mice (8 weeks old) (right 
side) following oronasal inoculation with 105 TCID50 MCMV HaNa1. Ten percent homogenates 
of tissue from 3 mice at each time point were prepared for titration. For each value, mean and 
standard deviation (SD) are shown. The detection limit of the titration assay is shown as dashed 
line. 
4.3.2. Detection of viral antigens in various tissues  
Results of immunofluorescence analysis are represented in Figure 4.2. The 
MCMV-infected cells were detected in the nasal mucosa (neonatal, 0.22 ± 0.08/10 
mm2; adult, 0.17 ± 0.06/10 mm2, at 5dpi), NALT (neonatal, 0.55 ± 0.10/10 mm2; adult, 
0.30 ± 0.08/10 mm2, at 5dpi), and submandibular glands (neonatal, 2.07 ± 0.17/10 
mm2; adult, 1.39 ± 0.64/10 mm2, at 10dpi) of both neonatal and adult mice. The 
MCMV-infected cells were only observed in the lungs (0.08 ± 0.02/10 mm2, at 7dpi) 
and kidneys (0.36 ± 0.05/10 mm2, at 14dpi) of neonatal mice.  
Results of double immunofluorescence analysis on nose sections are represented in 
Figure 4.3. Since both neonates and adults gave similar results, only staining of 
samples from infected neonatal mice were presented here. In the olfactory epithelium, 
viral proteins were expressed in both olfactory neurons and sustentacular cells. In the 
NALT, viral proteins were expressed in both macrophages and dendritic cells.  
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Figure 4.2.  MCMV antigen expression (arrowhead) and quantification of MCMV 
antigen-positive cells in various tissues of infected mice (n=3). Representative immunofluorescent 
images are shown. Cell nuclei were stained with Hoechst (blue). MCMV antigen-positive cells 
cells were detected in the nasal mucosa and NALT of infected neonatal and adult mice at 5 dpi, in 
the lungs of infected neonatal mice at 7 dpi, in the submandibular glands of neonatal and adult 
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mice at 10 dpi, in the kidneys of infected neonatal mice at 14 dpi. Scale bar = 100 µm. The 
number of MCMV antigen-positive cells detected in these tissues at corresponding time points 
was determined. For each value, mean and standard deviation (SD) are shown. 
 
Figure 4.3. Identification of MCMV+ cells in the nasal mucosa and NALT. Representative 
immunofluorescent images are shown. Cell nuclei were stained with Hoechst (blue). In the 
olfactory epithelium, viral proteins were detected in both olfactory neurons and sustentacular cells. 
In the NALT, viral proteins were found in both macrophages and dendritic cells. Scale bar = 50 
µm. 
4.3.3. Characteristics of antibodies after primary MCMV infection 
None of the animals developed detectable MCMV-specific IgM antibodies. From 10  
dpi, adult mice developed detectable MCMV-specific IgG antibodies, while in 
neonatal mice they appeared only from 14dpi. The levels of MCMV-specific IgG 
antibodies in neonates remained significantly lower than those in adult mice at 17 dpi 
(P < 0.05) (Figure 4.4A). Analysis of IgG isotypes demonstrated that the predominant  
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Figure 4.4.  Characteristics of antibodies from infected neonatal and adult mice. (A) Total 
anti-MCMV IgG levels in infected neonatal (open circle) and adult (closed circle) mice. Dotted 
and solid lines represent the mean of 3 neonatal mice and 3 adult mice at each time point, 
respectively. The SD is shown. The detection limit for the IPMA assay is shown as a dashed line. 
(B) MCMV-specific IgG1 and IgG2a levels in infected neonatal (open circle) and adult (closed 
circle) mice. The lines represent the mean of 3 mice at each time point, respectively. The SD is 
shown. The detection limit for the IPMA assay is shown as a dashed line. (C) Neutralizing 
antibody titers of adult mice. The line represents the mean of 3 adult mice at each time point. The 
SD is shown. (D) IgG avidity index in plasma from infected neonatal (open circle) and adult 
(closed circle) mice. The plasma at 17 dpi and 49 dpi were tested. The plasma from infected 
neonatal mice after 6 months were tested as a positive control.  
MCMV-specific antibody isotype was IgG2a for infection in both neonates and adults 
and MCMV-specific IgG1 was only detected at 49 dpi (Figure 4.4B). Other isotypes 
were not found during the course of the experiment (data not shown). In adult mice, 
neutralizing antibodies were not detected until 28 dpi and remained very low (1:2) at 
49 dpi (Figure 4.4C). Due to the limited amount of plasma, neutralizing antibodies of 
neonatal mice could not be tested. IgG avidity was determined for each mouse by 
using the plasma sample of 17dpi and 49 dpi. In each mouse, IgG avidity increased 
with time. Within 49 dpi all mice developed low-avidity MCMV-specific IgG 
antibodies (Figure 4.4D). We also tested the plasma from infected mice at 180 dpi and 
the avidity index was close to 50%, indicating that the time frame for antibody 
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maturation is more than 6 months.  
4.4. Discussion 
After oronasal inoculation, infectious virus was first detected in the nasal mucosa and 
was recovered throughout the whole course of the experiment. This indicates that 
virus replication starts in the nose and persists at this site. Thus, the nasal cavity likely 
serves as a previously undiscovered portal of entry and site of persistence for MCMV. 
Immunofluorescence showed that in the nose the virus targets the olfactory epithelium 
and NALT of nasal mucosa. This finding may be of clinical importance. It is notable 
that the presence of HCMV DNA in the nasal mucosa (8-11) and the tonsillar tissues 
(12, 13) of humans has been confirmed. Rodent NALT is considered to be the 
equivalent of the Waldeyer’s ring in humans (14, 15). Therefore, we extrapolate that 
the Waldeyer’s ring might provide a portal of entry for HCMV in humans. 
Due to a combination of intranasal and oral inoculation, the latter was expected to 
contribute to MCMV infection as HCMV is usually believed to orally infect humans. 
Surprisingly, infectious virus was not found in oral mucosa, pharynx, esophagus, and 
the intestinal tract, which is consistent with a previous study (16). They reported that 
MCMV infected cells were not found in the oral cavity, esophagus, and the 
gastrointestinal tract after oral inoculation. In fact, the mouse oral mucosa is mainly 
lined by variably orthokeratinized squamous epithelium, whereas the human oral 
mucosa is composed of non-keratinized- to slightly parakeratinized-stratified 
squamous epithelium (17). This might partly explain why oral inoculation is not 
efficient for MCMV infection in mice. The nose is prominently used in murine social 
life. These differences do not mean that there is no relevancy between the murine 
MCMV model and HCMV infection. Due to the equivalency of NALT and the 
Waldeyer’s ring, the results presented here might suggest that the Waldeyer’s ring 
might be one of the entry sites for HCMV in humans. 
Previous studies using intranasal inoculation under anesthesia indicated that virus was 
detected as early as 1 or 2 dpi in lungs (16, 18). Our results were different from these 
reports. In our study, all mice were inoculated without anesthesia, which avoided 
direct inhalation of the inoculum into the lungs (19). Virus was not detected in lungs 
until 5 dpi and not detected in the trachea at any time point. These results indicate that 
lungs might not be the primary entry organ for MCMV.  
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Infections of neonatal mice were generalized in visceral organs. MCMV replicated in 
the kidneys of neonatal mice during the course of the experiment. This agrees with the 
findings that HCMV is shed in the urine of HCMV-infected infants (20). Also brains 
were infected in neonatal mice, but the virus load was extremely low and transient. 
This was different from the studies using intraperitoneal or intracerebral inoculation 
(21, 22), which caused severe nervous symptoms and even death. In contrast to 
neonatal mice, infectious virus was not found in multiple visceral organs of adult mice. 
We hypothesize that the replication of MCMV in visceral organs of neonatal mice is 
possible due to the immaturity of the innate immunity. Natural killer (NK) cells are 
key effector cells in the innate immunity. Neonatal NK cell’s function may differ 
from adults after a CMV infection (23). A previous study strongly suggested that NK 
cells contribute to the age-dependent resistance of mice to MCMV infection (24).  
Our previous results showed that MCMV Smith infection can cause produtive 
infection in visceral organs of adult mice (6). In contrast, MCMV HaNa1 infection 
appeared to be similar to the HCMV infection in healthy adults. The different 
phenotype might be attributed to the genomic difference between MCMV HaNa1 and 
Smith. It is well known that MCMV has evolved numerous genes (e.g. m157, m152, 
m144, m138, m04) that are invovled in modulation of the NK cell response (25). 
Several genes were compared between HaNa1 and Smith (data not shown). Among 
these genes, the m144 and m157 genes of HaNa1 showed several variations with 
Smith. The m144 gene product possibly serves as a ligand for inhibitory NK cell 
receptors (26-28). The m157 gene product serves as a ligand for activating NK cell 
receptors in Ly49H+ mice (29, 30). Therefore, the gene variations between 
low-passage and highly passaged strains might explain the different replication 
kinetics of different strains in the early stage of an MCMV infection. 
In the course of infection, IgM antibodies were not detectable in our study. A low 
sensitivity of the IgM IPMA test may be responsible for this finding. The IgG 
antibody kinetics of infected neonatal and adult mice were quite similar. Like in 
adults, the primary response in neonatal mice was biased strongly towards the IgG2a 
isotype, a marker of Th1 response. This is different from the widely reported 
preferential induction of Th2 response in neonatal mice when exposed to various 
antigens and vaccines (31, 32). In the early stage, the MCMV-specific IgG antibodies 
exhibited a low avidity. After 6 months, the avidity index of IgG reached 50%, which 
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is similar to that found during an HCMV infection. Avidity of IgG antibodies has 
been used as a clinical index for distinguishing recent primary infections from 
long-term HCMV infections (7). 
In conclusion, we have established intranasal infections (without anesthesia) of 
neonatal and adult mice with murine CMV HaNa1 strain, which mimic the range and 
extent of virus replication during natural primary HCMV infections in healthy infants 
and adults. These findings bring new insights in the pathogenesis of natural primary 
CMV infections. 
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Abstract  
Currently, there is no vaccine available against HCMV. In this study, we utilized a previously 
developed neonatal murine MCMV model to investigate whether oronasal inoculation of 
neonatal mice with an MCMV strain provides a protection against an infection with another 
MCMV strain in adulthood. BALB/c mice were oronasally inoculated with 105 TCID50 
MCMV HaNa1 or PBS at 3 days of age and challenged with 105 TCID50 MCMV Smith 10 
weeks later. In mock-inoculated mice, inoculation with MCMV Smith produced a typical 
systemic infection. In contrast, only low levels of virus replication occurred transiently in 
nasal mucosa of HaNa1-inoculated mice. No virus replication was detected in other organs. 
Whole IgG and neutralizing antibody titers increased after challenge. Like the primary 
infection in neonatal life, the IgG isotype response to MCMV was still dominated by IgG2a 
after challenge. Furthermore, the MCMV-specific CD8 T cell response was boosted in NALT, 
deep cervical LN and spleen in HaNa1-inoculated mice compared with mock-inoculated mice 
after challenge. Taken together, our results demonstrate that a protective immunity against an 
MCMV infection can be established during neonatal life. These results might bring new 
insights in the development of vaccine strategies against HCMV infection in humans.  
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5.1. Introduction 
Human cytomegalovirus (HCMV), an opportunistic herpesvirus, is a ubiquitous pathogen that 
infects approximately 50-100% of the adults worldwide. In immunocompetent individuals, 
HCMV causes asymptomatic infection, and then establishes a persistent or latent infection, 
while in immunocompromised hosts, HCMV infection can result in severe disease (1). 
HCMV is the most common congenital infection, affecting 0.2-2.2% of all live births. 
Approximately 10% of CMV-infected newborns present clinical signs and symptoms, such as 
small birth weight and microcephaly. Post-natal HCMV infection is usually asymptomatic 
but severe disease can develop in very premature babies. So far, there is no vaccine available 
which could prevent HCMV infection or lessen the burden of HCMV infection and disease, 
particularly in fetuses (2). The Institute of Medicine (IOM) of the National Academies of 
Sciences, Engineering, and Medicine of USA has ranked the development of an HCMV 
vaccine as top priority. Initial infection with HCMV commonly occurs during childhood (3) 
and young children have been documented as an important reservoir of infectious virus in the 
community. Therefore, vaccination should be performed early in life.  
Relative to older children and adults, human fetuses and newborns have an increased 
susceptibility to infection with HCMV, which is believed to be due to a less developed 
immunity. However, several data indicate that young children are able to develop an adaptive 
immune response against HCMV. Indeed, specific IgM and IgG can be detected in HCMV 
infected infants and HCMV-specific CD8 T cells are present at the same frequency as in 
adults (4). HCMV-specific CD8 T cells from congenitally infected infants produce cytokines 
in response to viral antigens (5). Compared with antibody response, CD8 T cells are believed 
to play a more critical role in the control of an acute HCMV infection. 
Due to the strict species-specificity of cytomegaloviruses (CMV), HCMV cannot be studied 
experimentally in animal models. Therefore, murine cytomegalovirus (MCMV) infection in 
mice has been widely used as a model for studying HCMV infections in humans (6). Thus far, 
general mechanisms of immunity to MCMV and HCMV have been reported to be similar. 
The mouse model has been used to test strategies for vaccination against HCMV. Previous 
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studies have shown that intraperitoneal or intranasal vaccination with a live attenuated 
MCMV strain in adult mice protects against a lethal MCMV challenge and decreases MCMV 
titers (100- to 500-fold) in the spleen of MCMV-vaccinated mice compared with 
mock-vaccinated mice after challenge (7-10). The question is now raised if a protective 
immunity could be induced in neonatal mice via a natural infection route.  
Recently, we have developed a neonatal murine model of a natural primary MCMV infection 
via oronasal exposure of the low-passaged strain HaNa1, which mimics the range and extent 
of virus replication that is associated with a natural primary HCMV infection in healthy 
infants (11). It is commonly believed that the immune system of murine neonates is immature 
and that immune responses are T helper (Th) 2 response-predominant (12-15). But we found 
that the primary antibody response to an MCMV infection in neonatal mice was biased 
strongly towards the IgG2a isotype, a Th1 response marker. This demonstrates that neonatal 
animals are able to develop an adult-like Th1 response following a primary MCMV infection. 
In addition, we have demonstrated that nasopharynx-associated lymphoid tissue (NALT) is 
the main entry site for MCMV upon natural infection in mice. A number of studies on 
respiratory viruses also provide direct evidence that NALT is an effective mucosal inductive 
site for humoral and cellular immune responses (16-20). The role of NALT in the immunity 
against a natural MCMV infection, however, remains to be elucidated.  
In this study, we utilized the previously developed neonatal MCMV infection model to study 
whether oronasal inoculation of neonates with MCMV can protect against a challenge with a 
heterologous strain. 
5.2. Materials and methods 
5.2.1. Mice, cells, and virus 
Neonatal (3 days old) specific pathogen-free BALB/c mice were bred at the Faculty of 
Veterinary Medicine of Ghent University. They were all kept in isolation and given food and 
water ad libitum. Primary BALB/c mouse embryonic fibroblasts (MEFs) were prepared by 
trypsinization of 16-17 days old fetuses from BALB/c mice and were cultured in minimum 
essential medium (MEM) with 10% fetal calf serum (FCS), 2% lactalbumin and a mixture of 
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antibiotics (100 U/ml penicillin, 100 µg/ml streptomycin and 50 µg/ml gentamicin). MCMV 
HaNa1 and Smith strains were used for the experiment and prepared as previously described 
(21).  
5.2.2. Inoculation and challenge 
Neonatal mice were inoculated at the age of 3 days. 105 TCID50 MCMV HaNa1 in 10 µl PBS 
was pipetted into the nares (2.5 µl) and mouth (7.5 µl) without anesthesia. Meanwhile, as a 
control, neonatal mice were inoculated in the same way with 10 µl PBS. Mice were 
challenged with MCMV Smith as adults, 10 weeks after the first inoculation. 105 TCID50 
MCMV Smith in 100 µl PBS was pipetted into the nares (25 µl) and mouth (75 µl) without 
anesthesia. All animal experiments were approved by the Ethical Committee of the Faculty of 
Veterinary Medicine of Ghent University (EC 2015/110). 
5.2.3. Virus titration 
At 7, 10, 14, 21 days post challenge (dpc), mice were sacrificed and various tissues were 
collected. Tissue homogenates (10%, wt/vol) were made for virus titration. Briefly, tissues 
were homogenized by using a pestle, a small volume of sterile sand and DPBS with 0.9 mM 
CaCl2, 0.5 mM MgCl2·6H2O and 0.002% phenol red, supplemented with 2% FCS and a 
mixture of antibiotics (100 U/ml penicillin, 100 µg/ml streptomycin and 50 µg/ml 
gentamycin). Afterwards, the supernatants were collected after centrifugation (2400g, 10min). 
Virus titration was performed on the second passage of MEFs. After 7 days, the presence of a 
cytopathic effect (CPE) was assessed by light microscopy (Olympus Optial Co., Hamburg, 
Germany) and virus titers were calculated as 50% TCID50 according to the Reed and Muench 
formula. 
5.2.4. Co-culture of peripheral blood mononuclear cells (PBMC)  
To examine the cell-associated viremia, co-culture assays were performed. Secondary MEFs 
(2×105/well) were seeded in 24-well plates two days prior to co-culture. PBMC were isolated 
as previously described (21). Freshly isolated PBMC were brought on the MEFs monolayer 
and covered with 1 ml carboxymethylcellulose (CMC) medium (1/4 2 × MEM, 1/4 2 × RPMI, 
1/2 2 × CMC supplemented with 5% FCS, 100 U/ml penicillin, 100 µg/ml streptomycin, 50 
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µg/ml gentamicin, 0.1 mM non-essential amino acids and 1 mM sodium pyruvate). 
Afterwards, the plates were centrifuged at 750 g for 10 min. Subsequently, the cells were 
cultivated at 37°C in an incubator for 8 days. Plaques were counted with a light microscopy 
(Olympus Optial Co., Hamburg, Germany).   
5.2.5. Determination of MCMV-specific antibody titers   
The MCMV-specific antibody titers were determined by an in-house developed 
immunoperoxidase cell monolayer assay (IPMA) as previously published (21). Briefly, 
twofold dilutions of heat-inactivated plasma (56°C water-bath, 30 min), starting with an 
initial dilution of 1:16 in PBS-Tween with 10% normal goat serum, were added to fixed 
monolayers of MEFs infected with MCMV in 96-well plates and incubated at 37 °C for 1 h, 
followed by a thorough washing. Biotinylated sheep anti-mouse IgG (GE healthcare, 1:200), 
biotinylated rat anti-mouse IgG1 (eBioscience, 1:100), biotinylated rat anti-mouse IgG2a 
(eBioscience, 1:100), biotinylated rat anti-mouse IgG2b (BioLegend, 1:100), biotinylated 
goat anti-mouse IgG2c (Abcam, 1:100), or biotinylated rat anti-mouse IgG3 (BioLegend, 
1:100) were added to the plates and incubated at 37 °C for 1 h. After three washes, 
streptavidin-biotin horseradish peroxidase complex (GE, 1:200) was added to the wells and 
incubated at 37 °C for 1 h. Finally, NaAc-AEC-H2O2 was added into each well at room 
temperature (RT) for 30 min and then the reaction was stopped with PBS. The IPMA titers 
were calculated as the reciprocal value of the highest plasma dilution that gives a visual 
staining of infected MEFs, as determined by light microscopy. 
5.2.6. Virus neutralization assay 
At day one, serial twofold dilutions of heat-inactivated (56°C, 30min) plasma in MEM (from 
1:2 to 1:512) were incubated with an equal volume containing 500 TCID50 MCMV Smith for 
23 h at 37°C. Meanwhile, MEFs were trypsinized and seeded in 96-well plates with 2.5×104 
cells/well. After 23 h, 25 µl of guinea pig complement (0.5 µg/µl) per well was added to the 
plasma/virus dilution mixtures for incubating another 1h at 37°C in a 5% CO2 incubator. 
Then, the cell medium was removed and the mixtures of plasma/virus/complement were 
added to the confluent monolayers. The plates were kept for 7 days at 37°C. The neutralizing 
antibody titers were expressed as the reciprocal of the highest plasma dilution that was able to 
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completely block MCMV infection in MEFs. 
5.2.7. Determination of frequencies of MCMV-specific CD8 T lymphocytes   
Frequencies of IFN-γ-producing MCMV-specific CD8 T cells in the NALT, deep cervical 
lymph nodes (LN), and spleen were quantified by intracellular IFN-γ staining after 
stimulation with a specific peptide as previously described (22). Single-cell suspensions from 
the NALT (pool), deep cervical LN, and spleen were prepared in blocking buffer (1 × PBS/ 
1% FCS). A peptide of IE1 (168YPHFMPTNL176) was synthesized at a purity of >90% 
(ProteoGenix, Schiltigheim, France), diluted, and used at a concentration of 10-6 M. After 6 h 
stimulation with the peptide, cells were stained with PE-labeled rat anti-mouse CD8 (clone 
53-6.7) (BioLegend, San Diego, CA), fixed and permeabilized, and then stained with 
APC-labeled rat anti-mouse IFN-γ (clone XMG1.2) (BioLegend, San Diego, CA). Samples 
were analyzed with a FACSCanto (BD Biosciences, San Jose, CA) using FACSDiva software 
(BD Biosciences, San Jose, CA). Frequencies were given as percentage of IFN-γ-secreting 
cells of total CD8+ T cells. 
5.2.8. Statistical analysis   
Data from experimental groups were compared using unpaired two-tailed student’s t test by 
Prism 6 software (GraphPad, San Diego, CA). Differences were statistically significant when 
P < 0.05. 
5.3. Results  
5.3.1. Neonatal primary infection with MCMV HaNa1 protects mice upon a secondary 
infection with MCMV Smith during adult life 
To determine whether the immunity raised upon a primary MCMV infection of neonatal mice 
can protect against or limit replication upon a subsequent challenge with a different strain 
during adult life, neonatal mice were inoculated with 105 TCID50 MCMV HaNa1 (HaNa1 
inoculation) or PBS (mock inoculation) and then were challenged with 105 TCID50 MCMV 
Smith 10 weeks later. After challenge, mice were monitored for their health condition (Figure 
5.1). None of the inoculated mice showed changes in their behavior. Body weight of 
mock-inoculated and HaNa1-inoculated group did not show significant differences. Despite 
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the absence of clinical signs, enlarged mandibular LN (P < 0.01 at 7 and 21 dpc), deep 
cervical LN (P < 0.01 at 7 dpc and P < 0.05 at 10 dpc), and spleen (P < 0.01 at 10 dpc and P 
< 0.05 at 14 dpc) were observed after challenge in the animals of the mock-inoculated group 
compared with the animals of the HaNa1-inoculated group.   
Virus titers of various tissues were analyzed by virus titration (Figure 5.2). Ten weeks after 
primary infection of neonatal mice with MCMV HaNa1 (at challenge), infectious virus was 
no longer detected in any of the analyzed tissues. In the mock-inoculated group, MCMV 
Smith established a typical systemic infection. Infectious virus was detected in nasal mucosa 
and submandibular glands at 7, 10, 14, 21 dpc, in lungs at 7, 10 dpc, and in spleen, liver, 
kidneys at 10, 14 dpc. In contrast, in the HaNa1-inoculated group infectious virus was absent 
in all analyzed tissues except for the nasal mucosa at 7 dpc. The number of PBMC isolated 
from whole blood (0.6 ml) of each mouse was followed in time after challenge (Figure 5.3). 
At 7 dpc, the mock-inoculated group showed a 2-fold increase in the number of PBMC (P < 
0.05) compared with that at challenge. Afterwards, it decreased close to normal again from 10 
days. The HaNa1-inoculated group also showed a significant increase in the number of 
PBMC (P < 0.05) at 7 dpc, but the number of PBMC of the animals in the mock-inoculated 
group was significantly higher than that in the HaNa1-inoculated group at 7 dpc. 
Cell-associated viremia was only detected in PBMC of the mock-inoculated group at 7 dpc 
(1.6 ± 0.49 infected cells per 106 PBMC), but was not detected in the PBMC of the 
HaNa1-inoculated group. At all other time points, cell-associated viremia was not detected in 
either mock- or HaNa1-inoculated groups.  
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Figure 5.1. Body weight and weight of lymphoid tissues in mock-inoculated (white column) (n=3) 
and HaNa1-inoculated (black column) (n=4) mice at different time points post challenge with MCMV 
Smith. Significant differences are indicated with one or two asterisk (*P < 0.05, **P < 0.01). 
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Figure 5.2. Neonatal infection with MCMV HaNa1 protects mice virologically upon challenge with 
MCMV Smith. Mice were oronasally inoculated with 105 TCID50 MCMV HaNa1 (black column) or 
PBS (white column) at 3 days of age and were challenged 10 weeks later with 105 TCID50 MCMV 
Smith. At 7, 10, 14, 21 dpc, nasal mucosa, lungs, spleen, submandibular glands, liver and kidneys 
were collected for virus titration on MEFs. Data are expressed as the means ± SD of the results of 3-4 
mice at each time point. The detection limit of the titration assay is shown as dashed line. 
 
Nasal mucosa
0 7 10 14 21
1
2
3
4
5
dpc
log
10
 TC
ID
50
 /g
Mock inoculated
HaNa1 inoculated
Spleen
0 7 10 14 21
1
2
3
4
5
dpc
log
10
 TC
ID
50
 /g
Liver
0 7 10 14 21
1
2
3
4
5
dpc
log
10
 TC
ID
50
 /g
Lungs
0 7 10 14 21
1
2
3
4
5
dpc
log
10
 TC
ID
50
 /g
Submandibular glands
0 7 10 14 21
1
2
3
4
5
dpc
log
10
 TC
ID
50
 /g
Kidneys
0 7 10 14 21
1
2
3
4
5
dpc
log
10
 TC
ID
50
 /g
Chapter 5: Oronasal inoculation with MCMV in neonatal mice induces protection       97 
____________________________________________________________________________________________________ 
 
 
 
Figure 5.3. Evaluation of number of PBMC, isolated from whole blood (0.6 ml) of each 
mock-inoculated (white column) and HaNa1-inoculated (black column) mice after challenge with 
MCMV Smith. Data are expressed as the means ± SD of the results of 3-4 mice at each time point. 
Significant differences are indicated with an asterisk (*P < 0.05).  
5.3.2. Humoral response is boosted upon challenge and still predominated by IgG2a as during 
primary infection 
Figure 5.4 shows the characteristics of the antibody response after challenge. At 7 dpc, the 
HaNa1-inoculated mice showed a slight increase in IPMA antibody (specific IgG) titers 
compared with that at challenge. During the following days the level of IgG titers did not 
further increase. The IPMA antibody (specific IgG) titers of mock-inoculated mice rose 
strongly upon MCMV challenge. The neutralizing antibody titers of HaNa1-inoculated mice 
rose significantly at 7 dpc, and then gradually declined to the level of that at challenge. The 
neutralizing antibody titer of non-inoculated mice was first detected at 10 dpc and peaked at 
14 dpc. The isotype specific IPMA showed that predominant IgG2a isotype responses were 
detected in HaNa1-inoculated mice and mock-inoculated mice after challenge. Other specific 
isotype antibodies were not detected (data not shown).    
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Figure 5.4. Antibody responses of mock-inoculated (open white box) and HaNa1-imnoculated 
(closed black box) mice upon challenge with MCMV Smith 10 weeks later. MCMV-specific IgG 
antibody titers were quantified by IPMA. Neutralizing antibody titers were determined by virus 
neutralization. MCMV-specific IgG1 and IgG2a antibody titers were determined with an IgG1 or 
IgG2a specific IPMA. Data are expressed as the means ± SD of the results of 3-4 mice at each time 
point. The detection limit of the titration assay is shown as dashed line. 
5.3.3. MCMV-specific CD8 T cell response is boosted upon challenge  
The number of specific CD8 T cells was determined in NALT, deep cervical LN and spleen 
at 0, 7 and 21 dpc (Figure 5.5). At 7 and 21 dpc, low levels of IFN-γ-producing CD8 T cells 
were detected in the NALT (0.13% and 0.51%), deep cervical LN (0.29% and 0.63%) and 
spleen (0.16% and 0.55%) of mock-inoculated mice. In contrast, challenge of HaNa1- 
inoculated mice with MCMV Smith revealed a remarkably boosted response in the NALT 
(7.00%) at 7 dpc compared with that at challenge (0.29%). Afterwards, the response declined 
(to 2.23%). In contrast to the rapid response in NALT, specific CD8 T cells responses in deep 
cervical LN and spleen slightly, gradually increased, from 0.59% (LN) and 0.26% (spleen) at 
7 dpc to 1.38% (LN) and 1.02% (spleen) at 21 dpc.  
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Figure 5.5. (A) Gating strategy for flow cytometry. (B) MCMV-specific CD8 T cell responses in 
NALT, deep cervical LN and spleen of mock-inoculated (white column) and HaNa1-inoculated (black 
column) mice upon challenge with MCMV Smith. At 0, 7 and 21 dpc, 3-4 mice were sacrificed in 
each group and analyzed either as a pool (NALT) or single samples (deep cervical LN and spleen). 
MCMV peptide-specific IFN-γ-secreting cells from various lymphoid tissues were quantified (% 
specific CD8 T cells (mean ± SD)). The percentage of specific CD8 T cells is shown (mean ± SD).  
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5.4. Discussion 
HCMV infection may have severe consequences in the unborn child and immunodeficient 
patients (1). However, an effective vaccine is not yet available. A report from the Institute of 
Medicine of the National Academy of Sciences placed HCMV in the highest priority category 
for vaccine development (23). Currently, it has become clear that reinfection with new 
HCMV strains may be a relatively common event among children in a community (24). Thus, 
primary HCMV infection in some young children fails to prevent against reinfection during 
subsequent exposure to HCMV, suggesting that the immunity established by a natural 
HCMV infection is not fully protective. This argues that for a full protection, an HCMV 
vaccine may need to induce a response superior to that induced by natural immunity. Because 
young children are considered as a reservoir for horizontal transmission to adults and other 
children (3), vaccination strategies in early life should be taken into account.  
Recently, we have developed a murine model, which mimics the range and extent of virus 
replication during natural primary HCMV infections in healthy infants (11). Based on this 
model, we wanted to examine if young animals are able to develop an effective protection 
after a natural primary infection against a heterologous challenge under experimental 
conditions.   
In the present study, we showed that upon primary infection with MCMV HaNa1, mice were 
pathologically and virologically protected against a challenge with MCMV Smith. In naive 
mice, inoculation with MCMV Smith resulted in a typical systemic infection. Mice exposed 
to MCMV HaNa1 during neonatal life did not suffer from a productive infection in any organ 
after challenge with MCMV Smith in adulthood except for a low level of virus replication in 
the nasal mucosa at 7 dpc. The fact that we observed a strong protection against an acute 
MCMV Smith infection argues that an effective immune response can be raised during early 
life of mice and is strongly protective upon exposure to other strains during adult life. 
Although many previous studies suggested that neonates are immunodeficient, it has recently 
become apparent that human infants or neonatal mice are competent to develop significant 
immune responses against infectious agents or vaccine antigens (15, 25, 26). Therefore, such 
responses could be induced by vaccination and expanded by revaccination in early life.  
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In this study, we not only examined the pathological and virological protection in neonates 
inoculated with MCMV HaNa1 and challenged with MCMV Smith but also analyzed the 
immunological boost effect. We previously demonstrated that neonatal mice were able to 
develop a humoral response to primary MCMV HaNa1 infection. Our present results indicate 
that both whole IgG antibody titers and neutralizing antibody titers increased after challenge, 
which is in line with a previous report that mice inoculated during neonatal life showed an 
enhanced antibody response after challenge, which is indicative for the generation of an 
immunological memory (27). It is widely reported that neonatal mice usually develop a Th2 
bias in immune response, characterized by the preferential production of IgG1 antibodies on 
exposure to a variety of antigens and vaccines (28). However, our previous results showed 
that following primary infection the IgG antibody response to MCMV is dominated by an 
IgG2a antibody response, a marker of Th1 response. Here, like the primary infection, this 
bias towards IgG2a was maintained after challenge with MCMV Smith in adulthood. The 
Th1 response is characterized by evoking a cell-mediated immune response to intracellular 
pathogens (29), while Th2 response is required to stimulate B-cells into proliferation and to 
increase neutralizing antibody production (29). Currently, most of the vaccine strategies 
mainly focus on the induction of potent neutralizing antibodies (30). However, it is 
well-known that the transmission of CMV in vivo is cell-associated (31). Therefore, the Th1 
response might play a much more important role than the Th2 response in the control of 
CMV infection. When designing vaccines against HCMV, the ability to elicit a Th1 response 
should be considered. 
The control of HCMV disease correlates with the strength of the cytotoxic T-cell response to 
HCMV (32). Similarly, the CD8 T cell response has been shown to be important for the 
control of an acute MCMV infection (33-35). Although there were no reports about CD8 T 
cell response in neonatal mice to MCMV previously, studies on other viruses have shown 
that neonatal mice are able to mount a CD8 T cell response against a viral infection (28, 
36-38). In the present study, we observed a boost in CD8 T cell responses in NALT, deep 
cervical LN and spleen after challenge. Intriguingly, this boost was rapidly and strongly 
induced in NALT, most probably due to the replication of MCMV in this organ in contrast 
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with deep cervical LN and spleen. 
In rodents, NALT is described as paired aggregates of organized lymphoid tissues at the 
bottom of the nasopharyngeal duct and is considered as the equivalent of the Waldeyer’s ring 
in humans (39). In children under two years, NALT is present in addition to the Waldeyer's 
ring (40). While the NALT disappears in humans by the age of two, the Waldeyer's ring 
persists throughout life. NALT has been shown to be an effective mucosal inductive site for 
virus-specific humoral and cellular immune responses (16, 17, 19, 20). This might be of 
significance for the design and development of an HCMV vaccine. Oronasal exposure is 
believed as one of the natural HCMV transmission routes (3). NALT and the Waldeyer’s ring 
of young children are hypothesized as the entry site for natural HCMV infection. Therefore, 
NALT and the Waldeyer’s ring could be useful in vaccination strategies in young children 
(41, 42). Compared with the traditional intramuscular vaccination route, oronasal vaccination 
might be more promising. 
In conclusion, our results demonstrated that the protective immunity against MCMV 
infection could be established during neonatal life by oronasal inoculation. These results 
might bring new insights in the development of vaccine strategies against HCMV. 
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During the past half century, human cytomegalovirus (HCMV) has been recognized 
as a serious viral pathogen in humans (1, 2). The genetic background and 
immunological status of the host appear to be critical factors in determining the 
outcome of the infection. Generally, HCMV causes asymptomatic infections in 
healthy hosts, but in immunocompromised hosts HCMV leads to severe 
manifestations. Although recent studies in molecular biology have substantially 
advanced our understanding of HCMV replication and gene expression in vitro, in 
vivo studies have been hindered by the strict species specificity.  
The infection of mice with murine cytomegalovirus (MCMV) has been used as a 
useful model for studying HCMV pathogenesis in primary infection, establishment of 
latency, and reactivation (3). Several factors influence the outcome of MCMV 
infection, such as virus strain, inoculation routes, mouse strain and age. The most 
commonly used MCMV strain is the Smith strain, but it is known that this highly 
passaged strain has acquired significant genetic and biological differences compared 
to early passages of the Smith isolate (4). Therefore, there might be doubts on the 
relevancy of using this strain as a model for natural CMV infections. Indeed, for 
HCMV it has been demonstrated that extensively passaged laboratory strains show 
significant biological differences compared to low-passage clinical isolates (5). 
Therefore, the use of low-passage isolates is necessary. MCMV infection in adult 
mice has been studied with a variety of inoculation routes (3). Most studies have used 
artificial, usually intraperitoneal, routes of inoculation. So far, the question how 
MCMV replicates in vivo via a natural infection route has not been answered. 
Generally, intranasal and oral routes without anesthesia are widely accepted as natural 
infection routes.  
Recently, we isolated a new MCMV strain, HaNa1, from M. m. domesticus. In a 
previous study, it was demonstrated that there were obvious differences in replication 
kinetics (in vitro and in vivo) between the highly passaged MCMV Smith strain and 
the low-passage HaNa1 strain (6). In this thesis, the low-passage MCMV HaNa1 was 
used to obtain a better understanding of other determinants of pathogenesis of natural 
MCMV infections in mice, such as inoculation route, mouse strain and age. 
 
Ø The use of an oronasal inoculation route (without anesthesia) mimics 
natural exposure of CMV infection 
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The pathogenesis of MCMV infection in mice has been studied using a variety of 
inoculation routes (3). Most studies have employed the intraperitoneal route, which 
results in the direct infection of visceral organs, such as spleen and liver (7), and also 
does not allow to explore the entry site of natural exposure of MCMV. Inoculation 
routes mimicking the natural exposure of CMV infection have not been used, and the 
entry site of MCMV upon natural exposure has not yet been clearly determined over 
the past half a century.  
In this thesis, the oronasal inoculation route was used in all animal experiments. After 
oronasal inoculation, infectious virus was first detected in the nasal mucosa, which 
indicates that virus replication starts in the nose. Thus, the nasal cavity likely serves as 
the portal of entry for MCMV. Immunofluorescence staining showed that in the nose, 
virus targets the olfactory epithelium and NALT of the nasal mucosa, which may be 
of clinical importance. HCMV DNA has been detected in the nasal mucosa (8-11) and 
the tonsillar tissues (12, 13) of humans. Rodent NALT is considered to be the 
equivalent of the Waldeyer’s ring in humans (14, 15). Therefore, we extrapolate that 
the Waldeyer’s ring might provide a portal of entry for HCMV in humans. 
Previous studies using intranasal inoculation under anesthesia indicated that virus was 
detected as early as 1 or 2 dpi in lungs and lungs were thought as the entry site of 
natural exposure to MCMV (16, 17), which differs from our resuts. In our study, all 
mice were inoculated without anesthesia, which avoids direct inhalation of the 
inoculum into the lungs (18). Virus was not detected in lungs until 5 dpi and not 
detected in the trachea at any time point. These results clearly indicate that lungs 
might not be the primary entry organ for MCMV.  
The poor infectivity of oral MCMV was surprising, as HCMV is usually believed to 
transmit orally via saliva. Infectious virus was not found in oral mucosa, pharynx, 
esophagus, and the intestinal tract, which is also consistent with a previous study (16). 
In fact, the mouse oral mucosa is mainly lined by variably orthokeratinized squamous 
epithelium, whereas the human oral mucosa is composed of non-keratinized- to 
slightly parakeratinized-stratified squamous epithelium (19). This might partly explain 
why oral inoculation is not efficient for MCMV infection in mice. In addition, the 
nose features more prominently in murine social life and mice do not have tonsillar 
tissues in the oral cavity. Therefore, it is understandable that NALT is the main entry 
site for natural exposure to MCMV.   
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Ø Low-passage MCMV HaNa1 replication clearly differs between BALB/c, 
C57BL/6 and NOD mice   
Previous reports with highly virulent salivary gland derived MCMV (SGV) showed 
that, in BALB/c mice, intraperitoneal or intranasal inoculation with MCMV SGV 
results in an extensive multi-organ replication (20-22). Although there is a trend 
towards relatively lower virus titers in the tissues of resistant C57BL/6 and NOD mice 
compared with susceptible BALB/c mice, a multi-organ infection could still be 
observed in C57BL/6 and NOD mice (20-22). Furthermore, there is no correlation 
between the virus titers reached in the target organs and the time of onset and titers of 
IgG antibody produced among different inbred mouse strains (23). By comparing the 
replication kinetics of low-passage MCMV HaNa1 in three inbred mouse strains 
(BALB/c, C57BL/6 and NOD) upon oronasal inoculation (Chapter 3), we found that 
replication differences between mouse strains were much more pronounced. In 
BALB/c mice, a persistent productive infection was detected in nasal mucosa and 
submandibular glands till the end of experiment. C57BL/6 mice showed a more 
restricted MCMV replication. MCMV replication was strongly reduced in the nasal 
mucosa and productive replication was even blocked in the submandibular glands. In 
NOD mice, infectious virus was even not detected in the nasal mucosa and 
submandibular glands. There was a clear correlation between the extent of virus 
replication and the antibody response. These data showed that the choice of mouse 
strain is very important in studying MCMV infection when using a low-passage 
MCMV strain. 
The differences in susceptibility to MCMV infection between the different inbred 
mice may be related to the susceptibility of host target cells to MCMV. By comparing 
the replication kinetics of MCMV in splenic monocytic cells, a major carrier cell in 
MCMV systemic dissemination (24), from BALB/c and C57BL/6 mice, we found that 
splenic monocytic cells of BALB/c mice are more susceptible to MCMV infection 
than those of C57BL/6 mice. Besides the susceptibility of host target cells, previous 
studies have shown that the murine susceptibility to MCMV is also associated with 
the NK cell response, which involves the self-MHC-I haplotype and the Ly49 family 
of NK cell receptors (25). Upon MCMV infection, an effective NK cell response is 
mainly mediated by the Ly49 receptors (26). Under normal conditions, inhibitory 
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Ly49 receptors recognize self-MHC-I molecules and NK cell activation is prevented. 
After an MCMV infection, MHC-I molecules are down-regulated, leaving inhibitory 
Ly49 receptors unengaged, which results in NK cell activation (25). Each mouse 
strain has a unique MHC-I haplotype. The number of Ly49 haplotypes (including 
activating and inhibitory receptors) varies among the different mouse strains (27). The 
affinity of each Ly49 receptor for a given MHC-I haplotype is different. Therefore, 
the ability of binding of MHC-I and Ly49 receptors and to mount an effective NK cell 
response varies among different mouse strains, which may have an impact on their 
susceptibility to an MCMV infection. Besides the NK cell response, CD8 T cells play 
a vital role in viral clearance during acute infection. CD8 T cell response may vary 
among different mouse strains. A recent study has shown that antiviral NK cell 
activities can shape the CD8 T cell response (28). In addition, the products of several 
MCMV genes (e.g. m152, m06, m04) can inhibit cytotoxic CD8 T cell function by 
binding MHC-I to reduce the recognition or preventing the transport of MHC-I to the 
cell surface (29-31). Due to the difference of MHC-I haplotype among different 
mouse strains, the effect of these viral gene products may differ. 
Our results with low-passage MCMV HaNa1 are different from previous reports with 
highly passaged strains in genetically resistant mouse strains, which might be in part 
attributed to gene variations. MCMV has several immuno-evasion genes, e.g. m157, 
m152, m144, m138, whose products mediate the antiviral NK cell response (32). We 
have compared these genes between HaNa1 and two laboratory strains, Smith and 
K181. Among these genes, the m157 and m144 gene of HaNa1 have nucleotide 
differences when compared with Smith and K181 strains. The m157 protein can be 
recognized not only by the activating Ly49H receptor but also by inhibitory Ly49H 
receptor. The m157 and m144 protein can serve as MHC-I homologues, whose 
recognition by inhibitory NK cell receptors (e.g. Ly49I) during infection can 
potentially prevent NK cell activation and target cell killing (33-36).  
 
Ø Outcomes of MCMV HaNa1 infection clearly differ between neonatal and 
adult mice, but neonatal mice can develop adult-like antibody responses.   
To mimic natural primary infection of HCMV in healthy infants and adults, neonatal 
and adult BALB/c mice were experimentally inoculated with MCMV HaNa1 
oronasally. The impact of age on the outcome of an MCMV infection upon oronasal 
112            Chapter 6 
____________________________________________________________________________________________ 
 
inoculation was clear from our results. Inoculation of neonatal mice resulted in 
generalized infection in visceral organs, which is similar to HCMV infection in 
infants. For instance, MCMV replicated in the kidneys of neonatal mice during the 
course of the experiment, which is in line with the findings that HCMV is shed in the 
urine of HCMV-infected infants (37). In contrast to neonatal mice, infectious virus 
was not found in multiple visceral organs of adult mice.The replication of MCMV in 
visceral organs of neonatal mice can be attributed to susceptibility of the target cells 
to MCMV. We compared the replication kinetics of MCMV in splenic monocytic 
cells, from neonatal and adult BALB/c mice. We found that splenic monocytic cells of 
neonatal mice are much more susceptible to MCMV infection than those of adult mice. 
We also found that the content of monocytic cells in neonatal spleen was higher than 
that of adult mice. These results might in part explain why infectious virus was 
detected in neonatal spleen and was disseminated to other visceral organs. In addition, 
the immaturity of the innate immunity in neonatal mice may also be involved. NK 
cells are key effector cells in the early stage of MCMV infection. Neonatal NK cell 
function may differ from adults after a CMV infection (38). A previous study strongly 
suggested that NK cells contribute to the age-dependent resistance of mice to MCMV 
infection (39).  
In the course of infection, the IgG antibody kinetics of infected neonatal and adult 
mice were quite similar. Like in adults, the primary response in neonatal mice was 
biased strongly towards the IgG2a isotype, a marker of Th1 response. This is different 
from the widely reported preferential induction of a Th2 response in neonatal mice 
when exposed to various antigens and vaccines (40, 41). This demonstrates that 
neonatal animals are able to develop an adult-like Th1 response following a primary 
MCMV infection, driving us to further investigate a neonatal vaccination strategy. 
 
Ø Neonatal mice can develop a strong protective response against a 
heterologous strain infection in adulthood upon oronasal inoculation with 
MCMV HaNa1 
As mentioned in Chapter 4, the established neonatal murine model mimics the range 
and extent of virus replication that is associated with a natural primary HCMV 
infection in the early years of life (42). We demonstrated that neonatal animals are 
able to develop an adult-like Th1 response following a primary MCMV infection, and 
NALT is the main entry site for MCMV upon natural infection in mice. A number of 
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studies on respiratory viruses also provide direct evidence that NALT is an effective 
mucosal inductive site for humoral and cellular immune responses (14, 43-46). Based 
on these results, the question emerged whether young animals are able to develop an 
effective protective response after a natural primary infection against a heterologous 
challenge under experimental conditions. 
So far, no vaccine exists to prevent HCMV infection or lessen the burden of HCMV 
infection and diseases (47). Currently, reinfection with new HCMV strains may be a 
relatively common event among children in a community (48). Thus, primary HCMV 
infection in some young children fails to prevent reinfection during subsequent 
exposure to HCMV, suggesting that the immunity established by a natural HCMV 
infection is not fully protective. This argues that for a full protection, an HCMV 
vaccine may need to induce a response superior to that induced by natural immunity. 
Because young children are considered as a reservoir for horizontal transmission to 
adults and other children (1), vaccination strategies in early life should be taken into 
account.    
In Chapter 5, we utilized the established neonatal MCMV infection model to explore 
new CMV vaccination strategies. Neonatal mice were inoculated with MCMV HaNa1 
or PBS and then were challenged with MCMV Smith 10 weeks later. Upon primary 
infection with MCMV HaNa1, we showed that mice were pathologically and 
virologically protected against a challenge with MCMV Smith. In naive mice, 
inoculation with MCMV Smith resulted in a typical systemic infection. Mice exposed 
to MCMV HaNa1 during neonatal life did not suffer from a productive infection in 
any organ after challenge with MCMV Smith in adulthood except for a low level of 
virus replication in the nasal mucosa at 7 dpc. The fact that we observed a strong 
protection against an acute MCMV Smith infection argues that an effective immune 
response can be raised during early life of mice and is strongly protective upon 
exposure to other strains during adult life. Although many previous studies suggested 
that neonates are immunodeficient, more recently it became apparent that human 
infants or neonatal mice are competent to develop significant immune responses 
against infectious agents or vaccine antigens (38, 40, 49). Therefore, such responses 
could be induced by vaccination and expanded by revaccination in early life.  
Like during primary infection, the observed bias towards IgG2a was maintained after 
challenge with MCMV Smith in adulthood. The Th1 response is characterized by 
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evoking a cell-mediated immune response to intracellular pathogens (50), while Th2 
response is required to stimulate B-cells into proliferation and to increase neutralizing 
antibody production (50). Currently, the vaccine strategies mainly focus on the 
induction of potent neutralizing antibodies (51). However, it is well-known that the 
transmission of CMV in vivo is cell-associated (52). Therefore, the Th1 response 
might play a much more important role than the Th2 response in the control of CMV 
infection. When designing vaccines against CMV, the ability to elicit a prominent Th1 
response should be considered. The cell-mediated immune response was evaluated in 
our studies. The CD8 T cell response has been shown to be important for the control 
of an acute MCMV infection (53-55). Although there were no reports about CD8 T 
cell response in neonatal mice to MCMV previously, studies on other viruses have 
shown that neonatal mice are able to mount a CD8 T cell response against a viral 
infection (56-59). In the present study, we observed a boost in CD8 T cell responses 
in NALT, deep cervical LN and spleen after challenge.  
NALT in rodents is considered as the equivalent of the Waldeyer’s ring in humans 
(60). In children under two years, NALT is present in addition to the Waldeyer's ring 
(61). While the NALT disappears in humans by the age of two, the Waldeyer's ring 
persists throughout life. This might be of significance for the design and development 
of an HCMV vaccine. Oronasal exposure is believed to represent one of the natural 
HCMV transmission routes (1). NALT and the Waldeyer’s ring of young children are 
hypothesized as the entry site for natural HCMV infection. Therefore, NALT and the 
Waldeyer’s ring could be useful in vaccination strategies in young children (62, 63). 
Compared with the traditional intramuscular vaccination route, oronasal vaccination 
might be more promising. The NALT and Waldeyer’s ring are not only the entry site 
but also the immunologic effector, which may prevent infection in the primary target 
site. Young children have been documented as an important reservoir of infectious 
virus in the community. Therefore, infants and children should be considered as the 
main, potential vaccination targets. In addition, in order to induce strong Th1 response, 
the use of IL-2 or IL-12 as a new vaccine adjuvant might be worthwhile. In this thesis, 
we used the live field virus to immunize mice, which cannot be considered as a 
vaccine. In order to reduce the virulence/pathogenicity and the ability of latency of the 
field virus, known and certain genes should be deleted.  
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General conclusions 
Currently, most studies of MCMV infection in mice have used an intraperitoneal 
inoculation route with highly passaged virus strains. The use of an oronasal 
inoculation route and the low-passage MCMV HaNa1 in mice with different genetic 
background or age in this thesis brought new insights in the pathogenesis and vaccine 
strategies of CMV: 
1) A new murine model of primary MCMV infection has been developed, which 
mimics the pattern and extent of virus replication during natural primary HCMV 
infections in healthy infants and adults. The nose was found to be the entry site, 
where olfactory neurons and sustentacular cells in the olfactory epithelium and 
macrophages and DCs in NALT are the target cells. Like in adults, neonatal mice 
can develop a Th1 response, featuring a strong bias towards the IgG2a antibody 
isotype. 
2) Low-passage MCMV HaNa1 replication clearly differs between BALB/c, 
C57BL/6 and NOD mice upon oronasal inoculation; resistance in vivo to MCMV 
is in part due to a lower susceptibility of host target cells and is independent of T 
and B cells and γc signaling cytokine-dependent NK cell activities. 
3) Oronasal inoculation with low-passage MCMV HaNa1 in neonatal mice can 
induce a strong virological and immunological protection against an infection with 
MCMV Smith in adulthood. NALT plays a key role in the induction of an 
effective immune response during MCMV infection, which suggests that oronasal 
vaccination might be more promising compared with the traditional intramuscular 
vaccination route in the development of CMV vaccine strategies. 
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Summary  
During the past half century, human cytomegalovirus (HCMV) has been recognized 
as a serious viral pathogen in humans. Currently, little information is available on the 
natural primary infection of HCMV. Murine cytomegalovirus (MCMV) infection in 
mice has been widely used as a model for studying HCMV infections in humans. 
Most of the studies have used highly passaged strains and the intraperitoneal 
inoculation route. So far, the question how MCMV replicates in vivo via a natural 
infection route has not been answered. Therefore, this thesis aimed to obtain a better 
understanding of the pathogenesis of natural MCMV infection with the low-passage 
MCMV HaNa1 strain upon oronasal inoculation. 
In Chapter 1, an introduction was given on the taxonomy, the history, the general 
viral structure and replication cycle of MCMV, the current understanding of the 
pathogenesis of an MCMV infection and immune responses, and the development of 
vaccination strategies. In addition, given that the oronasal inoculation route was used 
in animal experiments in this thesis, a brief introduction was included on the anatomy 
of the nasal and oral cavities of the mouse. 
In Chapter 2, the aims of this thesis were formulated. 
In Chapter 3, three inbred mouse strains (BALB/c, C57BL/6 and NOD) were 
inoculated oronasally with 105 TCID50 MCMV HaNa1 strain. Viral replication was 
evaluated by virus titration and quantitative real-time PCR, and the antibody response 
was assessed by an immunoperoxidase cell monolayer assay (IPMA). In BALB/c 
mice, virus persisted in nasal mucosa (from 3 dpi) and submandibular glands (from 7 
dpi) until the end of the experiment (49 dpi). In C57BL/6 mice, infectious virus was 
only detected in nasal mucosa from 3 dpi until 21 dpi; viral genome was still 
detectable in nasal mucosa until 49 dpi. Although infectious virus was not detected in 
submandibular glands of C57BL/6 mice, viral genome was detected from 7 dpi until 
49 dpi. NOD mice appeared to be even more resistant with absence of any productive 
infection, and low-levels viral DNA loads were detected in the nasal mucosa. We 
demonstrated that there was a strong correlation between the degree of productive 
replication on the one hand and the time of first appearance and titer of 
MCMV-specific IgG antibody on the other hand. The deficiency of functional T and 
B cells and interleukin-2 (IL-2) common-γ chain (γc) did not increase the 
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susceptibility to MCMV by the use of NOD.SCID and NSG mice. In addition, using 
monocytic cells from BALB/c and C57BL/6 mice we found a susceptibility similar to 
that observed in vivo. Taken together, these results demonstrated that upon oronasal 
inoculation low-passage MCMV HaNa1 replication clearly differs between different 
inbred mice (BALB/c > C57BL/6 > NOD); resistance in vivo to MCMV is in part due 
to a less susceptibility of host target cells and is independent of T and B cells and γc 
signaling cytokine-dependent NK cell activities. 
In Chapter 4, neonatal and adult BALB/c mice were inoculated oronasally with 105 
TCID50 MCMV HaNa1. None of the mice showed clinical symptoms. In neonatal 
mice, a typical systemic infection occurred. In adult mice, viral replication was 
restricted to the nasal mucosa and submandibular glands. Infectious virus was not 
detected in trachea, oral mucosa, pharynx, esophagus, small intestines of both 
neonatal and adult mice at all time points. The nose was demonstrated to be the entry 
site. Double immunofluorescence staining showed that the infected cells in the nose 
were olfactory neurons and sustentacular cells in the olfactory epithelium and were 
macrophages and dendritic cells in nasopharynx-associated lymphoid tissues (NALT). 
Neonatal and adult mice developed a similar antibody response pattern, though the 
magnitude in neonatal mice was lower. In summary, a natural primary MCMV 
infection model was successfully established in neonatal and adult mice, which 
mimics the range and extent of virus replication during natural primary HCMV 
infections in healthy infants and adults.   
In Chapter 5, we utilized the developed neonatal murine MCMV model in Chapter 4 
to investigate whether oronasal inoculation of neonatal mice with an MCMV strain 
gives a protection against an infection with another MCMV strain in adulthood. 
Neonatal mice were oronasally inoculated with 105 TCID50 MCMV HaNa1 or PBS 
and then challenged with 105 TCID50 MCMV Smith 10 weeks later. In 
mock-inoculated mice, inoculation with MCMV Smith produced a typical systemic 
infection. In contrast, only low levels of virus replication occurred transiently in nasal 
mucosa of HaNa1-inoculated mice. No virus replication was detected in other organs. 
Whole IgG and neutralizing antibody titers increased after challenge. Like the primary 
infection in neonatal life, the IgG isotype response to MCMV was still dominated by 
IgG2a after challenge. Furthermore, the MCMV-specific CD8 T cell response was 
boosted in NALT, deep cervical LN and spleen in HaNa1-inoculated mice compared 
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with mock-inoculated mice after challenge. Taken together, these results demonstrate 
that a protective immunity against an MCMV infection can be established during 
neonatal life.    
In Chapter 6, all data obtained in this thesis were reviewed and discussed. General 
conclusions on the research data generated in this thesis were formulated in which the 
new insights in the pathogenesis of CMV infection and vaccination strategies were 
summarized. 
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Samenvatting  
Het humane cytomegalovirus (HCMV) is sinds de laatste halve eeuw erkend als een 
ernstig viral pathogen in mensen. Op dit moment is er slechts weinig informatie 
beschikbaar over een natuurlijke primaire infectie van HCMV. Een infectie met het 
muriene cytomegalovirus (MCMV) in muizen wordt wereldwijd gebruikt als een 
model voor het bestuderen van HCMV infecties in mensen. De meeste studies 
gebruiken stammen die reeds verschillende passages hebben ondergaan waarbij men 
intraperitoneaal inoculeert. Momenteel is het nog niet gekend hoe MCMV via een 
natuurlijke infectieroute vermeerdert in vivo. Zo komen we tot het doel van deze 
thesis, nl. een beter inzicht krijgen in de pathogenese van een natuurlijke MCMV 
infectie met de lag-passage MCMV HaNa1 stam na een oronasale inoculatie. 
In Hoofdstuk 1, werd een inleiding gegeven over de taxonomie, de geschiedenis, de 
structuur en replicatiecyclus van MCMV, de huidige kennis omtrent de pathogenese 
van een MCMV-infectie alsook over de immuunrespons en het ontwikkelen van 
vaccinatiestrategieën. Aangezien in deze thesis de oronasale inoculatieroute werd 
gebruikt bij dierexperimenten, werd hier ook een korte introductie gegeven omtrent de 
anatomie van de neus- en mondholte bij de muis. 
In Hoofdstuk 2, werden de doelstellingen van deze thesis geformuleerd. 
In Hoofdstuk 3, werden 3 inteeltmuizen (BALB/c, C57BL/6 en NOD) oro-nasaal 
geïnoculeerd met 105 TCDI50 van de MCMV HaNa1 stam. De virale replicatie werd 
bepaald aan de hand van virustitratie en kwantitatieve real-time PCR, en een 
immunoperoxidase cel monolaag assay (IPMA) werd gebruikt om de antistofrespons 
na te gaan. In BALB/c muizen persisteerde het virus in de neusmucosa (vanaf 3dpi) 
en de submandibulaire klieren (vanaf 7dpi) tot aan het einde van het experiment 
(49dpi). In C57BL/6 muizen werd er slechts infectieus virus gedetecteerd in de 
neusmucosa vanaf 3dpi tot 21dpi; viraal genoom was wel nog detecteerbaar in 
neusmucosa tot 49dpi.  Ondanks dat er geen infectieus virus gevonden werd in de 
submandibulaire klieren van de C57BL/6 muizen, werd er wel viraal genoom 
gedetecteerd vanaf 7dpi tot 49dpi. NOD muizen leken nog meer resistent te zijn en 
hadden geen productieve infectie; slechts lage levels viraal genoom werden 
gedetecteerd  in de neusmucosa. We hebben aangetoond dat er een sterke correlatie 
bestaat tussen enerzijds de graad van productieve replicatie en anderzijds het tijdstip 
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waarop de MCMV-specifieke IgG antistoffen verschijnen en hun titer. Deficiëntie van 
functionele T en B cellen en interleukin-2 (IL-2) common-γ chain (γc) verhoogde de 
gevoeligheid voor MCMV niet in NOD.SCID en NSG muizen. Bijkomend zagen we 
bij monocyten van BALB/c en C57BL/6 muizen een gelijkaardige gevoeligheid als in 
vivo. Kort samengevat tonen deze resultaten aan dat de replicatie van de MCMV 
HaNa1 stam, die slechts enkele passage heeft doorgemaakt, duidelijk verschilt tussen 
de verschillende inteelt muizenstammen na oro-nasale inoculatie. In vivo resistentie 
tegen MCMV komt gedeeltelijk door een mindere gevoeligheid van gastheer target 
cellen en is onafhankelijk van T- en B-cellen en van γc signaliserende, 
cytokine-afhankelijke NK-cel activiteiten. 
In Hoofdstuk 4, werden neonatale en volwassen BALB/c-muizen oronasaal 
geïnoculeerd met 105 TCID50 MCMV HaNa1. Geen van de muizen vertoonden 
klinische tekenen. Bij neonatale muizen trad een typische systemische infectie op. Bij 
volwassen muizen bleef de virale replicatie beperkt tot de nasale mucosa en 
submandibulaire klieren. Op geen enkel tijdstip kon infectieus virus gedetecteerd 
worden in de trachea, de orale mucosa, de pharynx, de oesophagus of de dunne 
darmen van zowel neonatale als volwassen muizen. De neus werd als intrede-plaats 
geïdentificeerd. Dubbele immunofluorescentiekleuring toonde aan dat ter hoogte van 
het olfactorisch epitheel de olfactorische neuronen en sustentaculaire cellen de 
geïnfecteerde cellen waren en dat macrofagen en dendritische cellen geïnfecteerd 
waren ter hoogte van het neus-geassocieerd lymfoïd weefsel. De antistofrespons 
vertoonde een gelijkaardig patroon bij neonatale en volwassen muizen, al was de 
antistofrespons kleiner bij neonatale muizen. Samengevat werd hier met succes een 
natuurlijk, primair MCMV-infectiemodel tot stand gebracht in neonatale en 
volwassen muizen, die, zowel in uitgestrektheid als hoeveelheid, nauw aansluit bij de 
virale replicatie die gezien wordt bij een natuurlijke primaire HCMV-infectie in 
gezonde kinderen en volwassenen. 
In Hoofstuk 5, gebruiken we het neonatale muriene MCMV model, zoals opgesteld in 
hoofdstuk 4, om na te gaan of een oronasale inoculatie van neonatale muizen met een 
MCMV stam bescherming biedt bij volwassen muizen, na infectie met een andere 
MCMV stam. De neonatale muizen werden oronasaal geinoculeerd met 105 TCID50 
MCMV HaNa1 of met PBS. 10 Weken later werden ze gechallenged met 105 TCID50 
MCMV Smith. Bij de niet-geinoculeerd muizen leidde de inoculatie met de MCMV 
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Smith tot een typische systemische infectie. Bij de muizen die geinoculeerd waren 
met HaNa1, werd daarentegen lage virustiters waargenomen en werd er een kortere 
replicatie waargenomen. In andere organen werd er geen virus replicatie 
waargenomen. De IgG en neutraliserende antistoffen titers namen toe na challenge. 
Zoals bij een primaire infectie bij neonati, werd na challenge, de anti-MCMV IgG 
isotype respons gedomineerd door IgG2a. In tegenstelling tot de niet-geinoculeerd 
muizen na challenge, werd de MCMV-specifieke CD8 T cell respons bij de 
HaNa1-geinoculeerd muizen geboosd in de NALT, de diepe cervicale LN en de milt. 
Deze resultaten tonen aan dat er bij een MCMV infectie beschermende immuniteit 
kan geinduceerd worden tijdens het neonatale leven. 
In Hoofdstuk 6, werden alle gegevens die in deze thesis bekomen werden, overlopen 
en bediscussiëerd. Tenslotte werden op basis van deze gegevens de algemene 
conclusies van deze thesis geformuleerd, waarin de nieuwe inzichten in de 
CMV-pathogenese en vaccinatiestrategieën samengevat werden. 
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